Citation Report
List of articles citing

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

DOI: 10.1056/nejmoa1113205
New England Journal of Medicine, 2012, 366, 883-892.

Source: https://exaly.com/paper-pdf/54311484/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2244	The Repurposing Drugs in Oncology (ReDO) Project. **2014**, 8, 442		89
2243	New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. **1986**, 113, 128-32		39
2242	Conference Record of the Thirty-Third Asilomar Conference on Signals, Systems, and Computers (Cat. No.CH37020). **1999**,		
2241	Stroke in the young: coming of age. **2002**, 59, 6-7		12
2240	Control System Synthesis by Root Locus Method. **2009**,		
2239	Appendix. **2009**,		
2238	Biocompatible nanopolymers: the next generation of breast cancer treatment?. **2012**, 7, 1467-70		28
2237	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. **2012**, 2, 109		60
2236	Advancing personalized cancer medicine in lung cancer. **2012**, 136, 1210-6		6
2235	The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach. **2012**, 65, 1057-61		8
2234	How many diseases are colorectal cancer?. **2012**, 2012, 564741		20
2233	The cancer antigenome. **2013**, 32, 194-203		172
2232	Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. **2012**, 23 Suppl 10, x211-8		17
2231	-Omics and cancer biomarkers: link to the biological truth or bear the consequences. **2012**, 21, 1229-35		18
2230	Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective. **2012**, 53, 314-20		11
2229	Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. **2012**, 2, 51		17
2228	BRAFV600E mutation and papillary thyroid cancer: chicken or egg?. **2012**, 97, 2295-8		23

2227	HER2 mutations in non-small-cell lung cancer can be continually targeted. **2012**, 30, 3318-9		24
2226	Promises from trametinib in RAF active tumors. *New England Journal of Medicine*, **2012**, 367, 171-2	59.2	7
2225	Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. **2012**, 12, 1545-57		12
2224	Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. **2012**, 109, E2998-3007		52
2223	Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. **2012**, 18, 6101-9		42
2222	Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. **2012**, 72, 6142-52		152
2221	Intratumor heterogeneity: seeing the wood for the trees. **2012**, 4, 127ps10		375
2220	Gene expression analysis as a tool in early-stage oral cancer management. **2012**, 30, 4053-5		6
2219	Genomic analysis and selected molecular pathways in rare cancers. **2012**, 9, 065004		7
2218	A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. **2012**, 4, 137ra75		141
2217	Imaging and genomics: is there a synergy?. **2012**, 264, 329-31		53
2216	GENERATION OF STATIONARY CONTROL POLICIES WITH BEST EXPECTED PERFORMANCE FOR A FAMILY OF MARKOV CHAINS. **2012**, 20, 423-440		1
2215	Resolution in patient data. **2012**, 19, 275-276		
2214	Occupational exposures and chronic obstructive pulmonary disease: incontrovertible evidence for causality?. **2012**, 185, 1252-4		9
2213	Network pharmacology for cancer drug discovery: are we there yet?. **2012**, 4, 939-41		35
2212	Therapie mit offenen Radionukliden bei multilokulˆer Skelettmetastasierung. **2012**, 35, 186-191		5
2211	Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. **2012**, 22, 2089-100		162
2210	Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. **2012**, 2, 390-2		9

2209	Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development. **2012**, 6, 569-83	5
2208	Can the exome and the immunome converge on the design of efficient cancer vaccines?. **2012**, 1, 579-580	21
2207	Personalized medicine: been there, done that, always needs work!. **2012**, 185, 1251-2	9
2206	Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?. **2012**, 9, 349-53	14
2205	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. **2012**, 12, 1245-8	8
2204	Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. **2012**, 1, 793-797	11
2203	Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. **2012**, 8, 1156-60	18
2202	Human tumor xenografts: the good, the bad, and the ugly. **2012**, 20, 882-4	36
2201	Imaging of multiple myeloma and related plasma cell dyscrasias. **2012**, 53, 1091-101	70
2200	Leveraging informatics, mobile health technologies and biobanks to treat each patient right. **2012**, 9, 849-857	3
2199	Tumour Formation: Number of Mutations Required. **2012**,	
2198	Genetics: Personalized medicine and tumour heterogeneity. **2012**, 9, 250	17
2197	ITERATIVE FEATURE PERTURBATION AS A GENE SELECTOR FOR MICROARRAY DATA. **2012**, 26, 1260003	19
2196	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. **2012**, 18, 6373-83	391
2195	Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. **2012**, 11, 2704-8	68
2194	ABSOLUTE cancer genomics. **2012**, 30, 620-1	15
2193	Biopsy and personalized medicine. **2012**, 9, 683-683	2
2192	Current management options for the small renal mass in a solitary kidney. **2012**, 57, 157-62	

2191	The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. **2012**, 72, 3901-5	15
2190	BAP1 loss defines a new class of renal cell carcinoma. **2012**, 44, 751-9	630
2189	Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications?. **2012**, 12, 667-70	3
2188	Reply to J. Perlmutter et al and D. Yee et al. **2012**, 30, 4588-4589	1
2187	Can intensive longitudinal monitoring of individuals advance cancer research?. **2012**, 17, 587-9	2
2186	Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?. **2012**, 2, 49	20
2185	Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model. **2012**, 2012, 518437	9
2184	miR-34 - a microRNA replacement therapy is headed to the clinic. **2012**, 3, 120	522
2183	An MBPhD programme in the UK: the UCL experience. **2012**, 12, 526-9	11
2182	Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes. **2012**, 11, M112.016998	72
2181	Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. **2012**, 30, 2929-30; author reply 2931	13
2180	Diagnostic applications of next generation sequencing: working towards quality standards/Diagnostische Anwendung von Next Generation Sequencing: Auf dem Weg zu Qualitätsstandards. **2012**, 36,	4
2179	Kidney cancer: bad news for personalized therapy. **2012**, 9, 179	1
2178	THE FUTURE OF GENOME-BASED MEDICINE. **2012**,	
2177	Overcoming the logistics of immune monitoring of cancer patients during clinical trials. **2012**, 2, 953-955	
2176	Profiling the immune stromal interface in breast cancer and its potential for clinical impact. **2012**, 7, 273-80	6
2175	Biomarkers, bundled payments, and colorectal cancer care. **2012**, 3, 16-22	10
2174	Conference Scene: Advances in breast cancer translational research. **2012**, 1, 197-199	

2173	Deriving clinical action from whole-genome analysis. **2012**, 9, 247-252	1
2172	Healthcare reform: it is getting personal. **2012**, 9, 405-412	2
2171	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. **2012**, 2012, 2-3	5
2170	The need to assess drugs selected from cancer genomic data prior to patient treatment. **2012**, 9, 463-466	2
2169	Applying biomarker testing to clinical practice in lung cancer. **2012**, 1, 145-154	
2168	Next-generation sequencing: application in liver cancer-past, present and future?. **2012**, 1, 383-94	15
2167	Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. **2012**, 10, 1379-86	4
2166	Cancer genomics meets clinical trials: the challenge ahead. **2012**, 9, 459-461	3
2165	Many genomes in one tumour. **2012**, 483, 248-249	
2164	Recent advances in treatment of metastatic colorectal cancer. **2012**, 2, 1109-1122	
2163	Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. **2012**, 120, 4191-6	251
2162	CLL clonal heterogeneity: an ecology of competing subpopulations. **2012**, 120, 4117-8	14
2161	Pharmacodynamic end points in early-phase oncology trials. **2012**, 2, 679-687	
2160	[Paediatric oncology in Hungary]. **2012**, 153, 803-10	1
2159	How cancer metabolism is tuned for proliferation and vulnerable to disruption. **2012**, 491, 364-73	652
2158	Molecular prognostic markers in gallbladder carcinoma. **2012**, 14, 571-2	1
2157	Unifying metastasis--integrating intravasation, circulation and end-organ colonization. **2012**, 12, 445-6	38
2156	Cancer in light of experimental evolution. **2012**, 22, R762-71	89

2155	Microfluidic: an innovative tool for efficient cell sorting. **2012**, 57, 297-307	110
2154	Personalized medicine: is it a pharmacogenetic mirage?. **2012**, 74, 698-721	49
2153	Cancer genomics and pathology: all together now. **2012**, 62, 647-59	5
2152	Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. **2012**, 93, 2606-2613	16
2151	Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. **2012**, 18, 3961-3971	113
2150	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. **2012**, 7, 253-65	44
2149	Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. **2012**, 2, 985-94	15
2148	Cancer. Heterogeneity and tumor history. **2012**, 336, 304-5	69
2147	It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. **2012**, 11, 2549-55	39
2146	Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. **2012**, 4, 784-93	52
2145	Odyssey of a cancer nanoparticle: from injection site to site of action. **2012**, 7, 606-618	260
2144	Personalised medicine in oncology: questions for the next 20 years. **2012**, 13, 448-9	14
2143	Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. **2012**, 65, 399-435	8
2142	Amino acids and mTORC1: from lysosomes to disease. **2012**, 18, 524-33	326
2141	Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. **2012**, 64, 1363-84	296
2140	Companion Diagnostics and the Drug□Diagnostic Codevelopment Model. **2012**, 73, 390-397	9
2139	Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics. **2012**, 6, 548-62	13
2138	Imaging mitochondrial redox potential and its possible link to tumor metastatic potential. **2012**, 44, 645-53	25

2137	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. **2012**, 150, 1107-20	1304
2136	A unifying theory of carcinogenesis, and why targeted therapy doesn't work. **2012**, 81 Suppl 1, S48-50	11
2135	Twenty-first century pathology sign-out. **2012**, 32, 639-50	2
2134	Companion diagnostics: emerging strategies and issues in pharmaceutical development. **2012**, 12, 561-3	4
2133	Evolutionary medicine: its scope, interest and potential. **2012**, 279, 4305-21	74
2132	Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. **2012**, 12 Suppl 1, S217-24	15
2131	Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. **2012**, 29, 707-27	7
2130	Clinical cancer genome and precision medicine. **2012**, 19, 3646-50	18
2129	The rebel angel: mutant p53 as the driving oncogene in breast cancer. **2012**, 33, 2007-17	199
2128	Heterogeneity and targeting of pancreatic cancer stem cells. **2012**, 18, 4277-84	61
2127	Overview of the cancer vaccine field: are we moving forward?. **2012**, 8, 1135-40	13
2126	Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. **2012**, 109, 14586-91	76
2125	What are we learning from the cancer genome?. **2012**, 9, 621-30	43
2124	Genomic landscape of non-small cell lung cancer in smokers and never-smokers. **2012**, 150, 1121-34	860
2123	The creation of an integrated health-information platform: building the framework to support personalized medicine. **2012**, 9, 621-632	2
2122	Intratumor heterogeneity: evolution through space and time. **2012**, 72, 4875-82	628
2121	Navigating cancer network attractors for tumor-specific therapy. **2012**, 30, 842-8	115
2120	The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. **2012**, 120, 2553-61	29

2119	Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. **2012**, 72, 4883-9	229
2118	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. **2012**, 107, 1009-16	28
2117	From single cells to deep phenotypes in cancer. **2012**, 30, 639-47	177
2116	BEAMing up personalized medicine: mutation detection in blood. **2012**, 18, 3209-11	39
2115	Applying next-generation sequencing to pancreatic cancer treatment. **2012**, 9, 477-86	37
2114	Targeted therapy in rare cancers--adopting the orphans. **2012**, 9, 631-42	25
2113	Cancer cell metabolism: one hallmark, many faces. **2012**, 2, 881-98	609
2112	The evolving concept of cancer and metastasis stem cells. **2012**, 198, 281-93	299
2111	Cancer stem cell definitions and terminology: the devil is in the details. **2012**, 12, 767-75	489
2110	Can network pharmacology rescue neutraceutical cancer research?. **2012**, 17, 807-9	9
2109	Evolution of the cancer genome. **2012**, 13, 795-806	424
2108	Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. **2012**, 2, 876-80	55
2107	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. **2012**, 30, 3077-83	154
2106	Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis. **2012**, 11, 74	21
2105	Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. **2012**, 10, 226	40
2104	Renal cancer biomarkers: the promise of personalized care. **2012**, 10, 112	48
2103	Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. **2012**, 10, 161	75
2102	Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. **2012**, 1, 12	82

2101	Overcoming implementation challenges of personalized cancer therapy. **2012**, 9, 542-8	96
2100	Cancer vaccines: are we there yet?. **2012**, 8, 1161-5	4
2099	Molecular pathology of non-small cell lung cancer: a practical guide. **2012**, 138, 332-46	95
2098	Therapeutic Drug Monitoring of Selected Anticancer Drugs. **2012**, 291-321	1
2097	Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. **2012**, 18, 1630-8	176
2096	Tumour heterogeneity: Darwin's finches. **2012**, 12, 317	4
2095	Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. **2012**, 13, 1073-86	26
2094	Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. **2012**, 11, 1404-15	51
2093	Intra-tumour heterogeneity: a looking glass for cancer?. **2012**, 12, 323-34	1320
2092	LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. **2012**, 40, 11189-201	666
2091	Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. **2012**, 11, 4344-51	125
2090	Cancer: Pinprick diagnostics. **2012**, 486, 482-3	19
2089	Reading cancer's blueprint. **2012**, 30, 581-4	3
2088	Breast cancer intratumor genetic heterogeneity: causes and implications. **2012**, 12, 1021-32	57
2087	Processing of primary brain tumor tissue for stem cell assays and flow sorting. **2012**,	12
2086	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. **2012**, 13, 782-9	413
2085	Choosing the right option for renal-cell carcinoma. **2012**, 13, 970-1	1
2084	Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. **2012**, 13, e554-61	44

2083	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. **2012**, 13, 1133-40		409
2082	Liposome imaging agents in personalized medicine. **2012**, 64, 1417-35		123
2081	Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. **2012**, 181, 1807-22		88
2080	Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model. **2012**, 326, 69-78		33
2079	Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. **2012**, 84, 301-13		60
2078	Cancer heterogeneity: origins and implications for genetic association studies. **2012**, 28, 538-43		20
2077	Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. **2012**, 136, 153-68		30
2076	Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. **2012**, 18, 717-22		30
2075	Emerging signaling pathways in hepatocellular carcinoma. **2012**, 1, 83-93		144
2074	Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?. **2012**, 5, 395-407		9
2073	Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. **2012**, 55, 8091-109		76
2072	Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies. **2012**, 4, 225-231		2
2071	Absolute quantification of somatic DNA alterations in human cancer. **2012**, 30, 413-21		1229
2070	Intratumor heterogeneity and branched evolution. *New England Journal of Medicine*, **2012**, 366, 2132; author reply 2133	59.2	14
2069	[Renal cancer biomarkers. What is justified?]. **2012**, 33 Suppl 2, 278-81		1
2068	What history tells us XXVIII. What is really new in the current evolutionary theory of cancer?. **2012**, 37, 609-12		3
2067	Neurofibromatosis Type 1. **2012**,		16
2066	Tumor phylogenetics. **2012**, 44, 368-368		1

2065	RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. **2012**, 4, 1106-45		45
2064	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. **2012**, 20, 1791-9		56
2063	Tumor heterogeneity and personalized medicine. *New England Journal of Medicine*, **2012**, 366, 956-7	59.2	170
2062	FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. **2012**, 2, 22		45
2061	Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. **2012**, 13, 591		175
2060	Challenges and opportunities in childhood cancer drug development. **2012**, 12, 776-82		37
2059	Cancer sequencing unravels clonal evolution. **2012**, 30, 408-10		32
2058	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. **2012**, 10, 56		48
2057	FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. **2012**, 31, 103		31
2056	Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET. **2012**, 2012, 438647		39
2055	Non-small cell lung cancer: the era of targeted therapy. **2012**, 3, 31-41		6
2054	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. **2012**, 2, 77-92		2
2053	Biopsy gives only a snapshot of tumour diversity. **2012**,		
2052	Origin of Cancer: Founder Clones. **2012**, 01,		
2051	Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. **2013**, 18, 1519-26		24
2050	[Intratumor heterogeneity, a Darwinian stumbling block towards personalized medicine?]. **2012**, 28, 1116-9		3
2049	To differentiate or not--routes towards metastasis. **2012**, 12, 425-36		461
2048	Combinatorial drug therapy for cancer in the post-genomic era. **2012**, 30, 679-92		670

2047 Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. **2012**, 4, 675-84 164

2046 State of the science: an update on renal cell carcinoma. **2012**, 10, 859-80 121

2045 Cancer chromosomal instability: therapeutic and diagnostic challenges. **2012**, 13, 528-38 264

2044 Intratumour heterogeneity. **2012**, 11, 354-354

2043 Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. **2012**, 12, 487-93 467

2042 Towards individualisation of treatment in endometrial cancer. **2012**, 106, 1581-2 2

2041 Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. **2012**, 18, 6519-30 51

2040 [Genetic variations of a tumor]. **2012**, 63, 587-8

2039 Evolution of tumour biology upon progression. Do we know our enemy?. **2012**, 14, 399-400

2038 M□glichkeiten und Grenzen der stratifizierenden Medizin am Beispiel der Onkologie. **2012**, 27, 196-202 1

2037 "Two" much of a good thing: telomere damage-induced genome doubling drives tumorigenesis. **2012**, 21, 712-4 3

2036 Harnessing the power of human tumor-derived cell lines for the rational design of cancer therapies. **2012**, 25, 406-8

2035 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". **2013**, 11, 137 18

2034 Modelling gene expression profiles related to prostate tumor progression using binary states. **2013**, 10, 37 4

2033 Reliability of receptor assessment on core needle biopsy in breast cancer patients. **2013**, 34, 987-94 11

2032 High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. **2013**, 119, 3034-42 138

2031 Cancer heterogeneity--a multifaceted view. **2013**, 14, 686-95 160

2030 Molecular Genetics of Pancreatic Cancer. **2013**, 1

2029	The growing complexity of HIF-1 s role in tumorigenesis: DNA repair and beyond. **2013**, 32, 3569-76	51
2028	Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?. **2013**, 32, 673-705	15
2027	Liquid biopsy: monitoring cancer-genetics in the blood. **2013**, 10, 472-84	1134
2026	Hsp90, an unlikely ally in the war on cancer. **2013**, 280, 1381-96	142
2025	A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. **2013**, 12, 4005-17	13
2024	The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. **2013**, 25, 569-77	50
2023	Next generation sequencing in cancer research and clinical application. **2013**, 15, 4	76
2022	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. **2013**, 14, 505	25
2021	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. **2013**, 13, 3	12
2020	Advances in bladder cancer imaging. **2013**, 11, 104	58
2019	Luminal breast cancer: from biology to treatment. **2013**, 10, 494-506	123
2018	Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. **2013**, 40, 668-76	26
2017	Histone modifications: implications in renal cell carcinoma. **2013**, 5, 453-62	15
2016	Single-cell sequencing-based technologies will revolutionize whole-organism science. **2013**, 14, 618-30	779
2015	Advanced HER2-positive gastric cancer: current and future targeted therapies. **2013**, 85, 350-62	49
2014	Predictive power of cell-to-cell variability. **2013**, 1, 131-139	19
2013	Prognostic value of proliferation markers expression in breast cancer. **2013**, 30, 523	11
2012	Dynamic imaging in medicine and network biology. **2013**, 27, 689-90	

2011	Antagonistic functional duality of cancer genes. **2013**, 529, 199-207	36
2010	Nutzenbewertung personalisierter Interventionen: Methodische Herausforderungen und Lösungsansätze. **2013**, 25, 173-182	6
2009	Alter Wein in neuen Schläuchen? Ethische Implikationen der Individualisierten Medizin. **2013**, 25, 223-231	9
2008	Effector CD4 and CD8 T cells and their role in the tumor microenvironment. **2013**, 6, 123-33	190
2007	Microengineered tumor models: insights & opportunities from a physical sciences-oncology perspective. **2013**, 15, 583-593	33
2006	Medulloblastoma stem cells: modeling tumor heterogeneity. **2013**, 338, 23-31	25
2005	Targeting angiogenesis in renal cell carcinoma. **2013**, 14, 2221-36	31
2004	Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. **2013**, 4, 1504	153
2003	Glycosylation enhances the anti-migratory activities of isomalyngamide A analogs. **2013**, 64, 169-78	5
2002	Next Generation Sequencing in Cancer Research. **2013**,	4
2001	Low-cost fabrication of centimetre-scale periodic arrays of single plasmid DNA molecules. **2013**, 13, 3367-72	3
2000	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. **2013**, 109, 827-35	79
1999	Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. **2013**, 62, 967-74	20
1998	A glimpse into past, present, and future DNA sequencing. **2013**, 110, 3-24	106
1997	Cancer Stem Cells: Prospective Isolation and Progress Toward Functional Biomarker Identification. **2013**, 1, 81-90	
1996	Breast Cancer Heterogeneity in Primary and Metastatic Disease. **2013**, 65-95	1
1995	Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. **2013**, 109, 1230-42	34
1994	Molecular Surgical Pathology. **2013**,	18

1993	FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. **2013**, 31, 1266-77	43
1992	Molecular targets on the horizon for kidney and urothelial cancer. **2013**, 10, 557-70	18
1991	Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. **2013**, 119, 1547-54	44
1990	Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. **2013**, 229, 515-24	73
1989	Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. **2013**, 45, 15-23	2
1988	Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution. **2013**, 2, 48-54	2
1987	Quantum dots-based in situ molecular imaging of dynamic changes of collagen IV during cancer invasion. **2013**, 34, 8708-17	39
1986	Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal. **2013**, 11, 198-200	1
1985	Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction. **2013**, 15, 1301-13	20
1984	THU-04 Rationale for intraarterial therapies of liver malignancies. **2013**, 45, S234	
1983	A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. **2013**, 3, 1440-8	65
1982	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. **2013**, 24, 350-352	3
1981	Of mice and men. **2013**, 19, 1140-1	3
1980	Unexpected long-term survival in a BRCA2 patient with metastatic carcinosarcoma associated with tamoxifen. **2013**, 4, 44-6	2
1979	Individualising treatment choices in a crowded treatment algorithm. **2013**, 11, 160-8	2
1978	Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. **2013**, 20, 1187-97	33
1977	Stress-Induced Mutagenesis. **2013**,	3
1976	Discovery of novel drugs for promising targets. **2013**, 35, 1271-81	11

1975	MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. **2013**, 46, 539-45	71
1974	Selection and adaptation during metastatic cancer progression. **2013**, 501, 365-72	200
1973	Understanding the tumor microenvironment and radioresistance by combining functional imaging with global gene expression. **2013**, 23, 296-305	14
1972	Companion diagnostics in oncology - current status and future aspects. **2013**, 85, 59-68	28
1971	The regulatory landscape for actively personalized cancer immunotherapies. **2013**, 31, 880-2	52
1970	Turning tumors into vaccines: co-opting the innate immune system. **2013**, 39, 27-37	72
1969	Inferring tumour purity and stromal and immune cell admixture from expression data. **2013**, 4, 2612	2572
1968	Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. **2013**, 12, 168-78	26
1967	Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. **2013**, 8, 2240-55	73
1966	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. **2013**, 8, 1381-97	6
1965	Cooperation and antagonism among cancer genes: the renal cancer paradigm. **2013**, 73, 4173-9	68
1964	From integrative genomics to therapeutic targets. **2013**, 73, 3483-8	16
1963	The clinical relevance of cancer cell lines. **2013**, 105, 452-8	341
1962	Can nanomedicines kill cancer stem cells?. **2013**, 65, 1763-83	100
1961	Real-time liquid biopsy in cancer patients: fact or fiction?. **2013**, 73, 6384-8	315
1960	Decoding the histone code: Role of H3K36me3 in mismatch repair and implications for cancer susceptibility and therapy. **2013**, 73, 6379-83	31
1959	Cancer genome landscapes. **2013**, 339, 1546-58	5058
1958	MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. **2013**, 49, 211-5	191

1957	Nanomedicine therapeutic approaches to overcome cancer drug resistance. **2013**, 65, 1866-79	489
1956	The role of cell density and intratumoral heterogeneity in multidrug resistance. **2013**, 73, 7168-75	47
1955	Cancer and the goals of integration. **2013**, 44, 466-76	24
1954	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. **2013**, 31, 2167-72	143
1953	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. **2013**, 19, 2240-7	1655
1952	Tumor metastasis: moving new biological insights into the clinic. **2013**, 19, 1450-64	544
1951	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. **2013**, 34, 725-38	68
1950	Can we deconstruct cancer, one patient at a time?. **2013**, 29, 6-10	16
1949	Incorporating spatial correlations into multispecies mean-field models. **2013**, 88, 052713	24
1948	Breast Cancer Biomarkers: Utility in Clinical Practice. **2013**, 5, 284	15
1947	High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. **2013**, 109, 1123-9	85
1946	Intratumor heterogeneity: nature and biological significance. **2013**, 78, 1201-15	49
1945	Introduction: sifting through the characterization of hematologic malignancies. **2013**, 50, 284-5	
1944	Dissecting social cell biology and tumors using Drosophila genetics. **2013**, 47, 51-74	45
1943	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. **2013**, 14, 1200-7	226
1942	Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. **2013**, 110, E2490-9	72
1941	Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. **2013**, 359-371	
1940	Computational optimisation of targeted DNA sequencing for cancer detection. **2013**, 3, 3309	20

1939	Development of therapeutic combinations targeting major cancer signaling pathways. **2013**, 31, 1592-605	194
1938	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. **2013**, 1, 251-61	57
1937	Origins of metastatic traits. **2013**, 24, 410-21	367
1936	Mechanisms governing metastatic dormancy and reactivation. **2013**, 155, 750-64	368
1935	Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. **2013**, 19, 3591-9	160
1934	Tumor Phylogenetics in the NGS Era: Strategies, Challenges, and Future Prospects. **2013**, 335-357	
1933	Mass spectrometry imaging for in situ kinetic histochemistry. **2013**, 3, 1656	47
1932	Strategies for improving outcomes in NSCLC: a look to the future. **2013**, 82, 375-82	26
1931	Targeted Sequencing Strategies in Cancer Research. **2013**, 137-163	2
1930	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. **2013**, 31, 3133-40	226
1929	Dynamics of tissue topology during cancer invasion and metastasis. **2013**, 10, 065003	7
1928	The causes and consequences of genetic heterogeneity in cancer evolution. **2013**, 501, 338-45	1473
1927	Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. **2013**, 6, 40	24
1926	[Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice)]. **2013**, 33, 24-37	4
1925	THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. **2013**, 14, R80	160
1924	The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. **2013**, 6, 17	22
1923	Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?. **2013**, 11, 214	47
1922	Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013). **2013**, 15, 594-604	2

1921	Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. **2013**, 57, 311-25	23
1920	Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". **2013**, 32, 403-21	33
1919	Human Somatic Variation: It's Not Just for Cancer Anymore. **2013**, 1, 212-218	4
1918	Emerging patterns of somatic mutations in cancer. **2013**, 14, 703-18	366
1917	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). **2013**, 130, 269-74	79
1916	High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. **2013**, 231, 433-440	111
1915	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. **2013**, 7, 776-90	116
1914	Personalized oncology in interventional radiology. **2013**, 24, 1083-92; quiz 1093	21
1913	Tumour heterogeneity and cancer cell plasticity. **2013**, 501, 328-37	1532
1912	Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences. **2013**, 84, 667-81	25
1911	Renal cell carcinoma with areas mimicking renal angiomyoadenomatous tumor/clear cell papillary renal cell carcinoma. **2013**, 44, 1412-20	35
1910	Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. **2013**, 63, 848-54	168
1909	Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas. **2013**, 44, 2106-15	18
1908	Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. **2013**, 13, 581-99	46
1907	The next-generation sequencing revolution and its impact on genomics. **2013**, 155, 27-38	655
1906	The molecular biology of renal cell carcinoma. **2013**, 40, 421-8	39
1905	Colorectal cancer stem cells and their implications for novel anticancer therapy. **2013**, 13, 461-8	
1904	Molecular markers to predict response to therapy. **2013**, 40, 444-58	17

1903	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. **2013**, 45, 1483-6	219
1902	Biomarker discovery. **2013**, 365-383	1
1901	Current frontiers in clinical research application of MALDI imaging mass spectrometry. **2013**, 10, 259-73	24
1900	Future of biosensors: a personal view. **2014**, 140, 1-28	9
1899	Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. **2013**, 163, 496-500	39
1898	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. **2013**, 5, 47	35
1897	Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. **2013**, 5, 101	36
1896	Molecular aspects of cancer cell resistance to chemotherapy. **2013**, 85, 1219-26	275
1895	Research in Computational Molecular Biology. **2013**,	9
1894	The genomic map of breast cancer: which roads lead to better targeted therapies?. **2013**, 15, 209	10
1893	Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines. **2013**, 5, 1272-81	18
1892	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. **2013**, 31, 3997-4013	2593
1891	The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. **2013**, 19, 6924-34	54
1890	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. **2013**, 110, 4009-14	1107
1889	Clinical and biological implications of driver mutations in myelodysplastic syndromes. **2013**, 122, 3616-27; quiz 3699	1169
1888	Advances in catheter-ablation treatment of AF. **2013**, 10, 63-4	6
1887	Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation. **2013**, 288, 27940-50	12
1886	Methods and challenges in timing chromosomal abnormalities within cancer samples. **2013**, 29, 3113-20	19

1885	How can attrition rates be reduced in cancer drug discovery?. **2013**, 8, 363-8	71
1884	Metabolism of kidney cancer: from the lab to clinical practice. **2013**, 63, 244-51	54
1883	Stochastic profiling of transcriptional regulatory heterogeneities in tissues, tumors and cultured cells. **2013**, 8, 282-301	26
1882	Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery. **2013**, 23, 99-108	70
1881	DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. **2013**, 5, 169ra10	190
1880	Deep sequencing in cancer research. **2013**, 43, 110-5	16
1879	Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. **2013**, 339, 543-8	550
1878	Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. **2013**, 44, 39-46	29
1877	Cancer pharmacogenomics: strategies and challenges. **2013**, 14, 23-34	154
1876	Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. **2013**, 341, 63-72	161
1875	Genomic medicine: new frontiers and new challenges. **2013**, 59, 158-67	50
1874	The decline and fall of the IGF-I receptor. **2013**, 228, 675-9	61
1873	Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. **2013**, 309, 37-8	12
1872	Proteomics and the search for biomarkers for renal cancer. **2013**, 46, 456-65	16
1871	Thoughts for a new year. **2013**, 13, 1	8
1870	Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. **2013**, 11, 5-12	27
1869	Predicting outcomes in radiation oncology--multifactorial decision support systems. **2013**, 10, 27-40	270
1868	The impact of tumor heterogeneity on patient treatment decisions. **2013**, 59, 38-40	7

1867	Next-generation sequencing in the clinic: promises and challenges. **2013**, 340, 284-95	206
1866	Potential role of genetic markers in the management of kidney cancer. **2013**, 63, 333-40	24
1865	Classification of mitocans, anti-cancer drugs acting on mitochondria. **2013**, 13, 199-208	163
1864	Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges. **2013**, 340, 220-6	20
1863	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. **2013**, 152, 714-26	1006
1862	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. **2013**, 31, 1039-49	357
1861	The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney. **2013**, 52, 165-73	25
1860	Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. **2013**, 132, 1547-55	73
1859	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. **2013**, 132, 1565-71	148
1858	Why imatinib remains an exception of cancer research. **2013**, 228, 665-70	42
1857	Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. **2013**, 15, 939-51	26
1856	Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. **2013**, 59, 392-5	17
1855	THU-03 Angiogenesis inhibition in cancer. **2013**, 45, S234	
1854	Targeted cancer therapy--are the days of systemic chemotherapy numbered?. **2013**, 76, 308-14	56
1853	Renal-cell carcinoma: a step closer to a new classification. **2013**, 14, 105-7	7
1852	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. **2013**, 14, 159-167	318
1851	Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. **2013**, 64, 994-1002	26
1850	Will nanomedicine deliver on its promise of changing therapeutics or remain an interesting and important research tool in cell biology and physiology?. **2013**, 454, 530-1	5

1849	Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas. **2013**, 44, 2116-25	27
1848	New options for second-line therapy of advanced renal cancer. **2013**, 14, 450-1	1
1847	From molecular imaging markers to personalized image-guided therapy. **2013**, 23, 1-2	3
1846	Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. **2013**, 15, 1371-8	65
1845	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. **2013**, 110, 21083-8	344
1844	Quantitative imaging in cancer evolution and ecology. **2013**, 269, 8-15	270
1843	Tackling the diversity of triple-negative breast cancer. **2013**, 19, 6380-8	120
1842	Molecular markers for targeted neoadjuvant rectal cancer therapy. **2013**, 2, 321-331	1
1841	Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. **2013**, 95, 74-82	12
1840	Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. **2013**, 67, 235-40	35
1839	Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. **2013**, 31, 639-46	26
1838	Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. **2013**, 5, 216-23	95
1837	Incorporate gene signature profiling into routine molecular testing. **2013**, 2, 28-33	3
1836	Reply from Authors re: James W.F. Catto, Shahrokh F. Shariat. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. Eur Urol 2013;63:855–. **2013**, 63, 857-858	
1835	Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?. **2013**, 216, 239-51	46
1834	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. **2013**, 49, 3076-82	25
1833	The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor. **2013**, 435, 408-13	18
1832	THU-02 Liver metastases of colorectal cancer: Is there a specific molecular signature?. **2013**, 45, S233-S234	

1831	Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. **2013**, 1834, 2347-59	21
1830	Progression from ductal carcinoma in situ to invasive breast cancer: revisited. **2013**, 7, 859-69	146
1829	Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?. **2013**, 82, 2353-8	4
1828	The challenge of gene expression profiling in heterogeneous clinical samples. **2013**, 59, 47-58	18
1827	The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. **2013**, 63, 855-7; discussion 857-8	4
1826	Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. **2013**, 13, 807-12	24
1825	Using functional genomics to overcome therapeutic resistance in hematological malignancies. **2013** , 55, 100-15	7
1824	Single-cell profiling of circulating tumour cells: a great leap forward. **2012**, 6, 1-2	
1823	The era of big trials is over. **2013**, 14, 12-4	2
1822	Prognosis of renal-cell carcinoma: recognising host genetics. **2013**, 14, 9-10	1
1821	New paradigms and future challenges in radiation oncology: an update of biological targets and technology. **2013**, 5, 173sr2	151
1820	A preclinical mouse model of invasive lobular breast cancer metastasis. **2013**, 73, 353-63	41
1819	Tracking cells in their native habitat: lineage tracing in epithelial neoplasia. **2013**, 13, 161-71	46
1818	Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. **2013**, 73, 1037-45	42
1817	Plasma-derived tumor DNA analysis at whole-genome resolution. **2013**, 59, 6-8	5
1816	Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. **2013**, 41, e67	301
1815	Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. **2013**, 23, 843-54	221
1814	Antibody-drug conjugates for the treatment of cancer. **2013**, 81, 113-21	175

1813	Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization. **2013**, 90, 51-8		17
1812	Riparian ecosystems in human cancers. **2013**, 6, 46-53		43
1811	Cancer stem cells as 'units of selection'. **2013**, 6, 102-8		50
1810	Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. **2013**, 6, 54-69		18
1809	Applying ecological and evolutionary theory to cancer: a long and winding road. **2013**, 6, 1-10		57
1808	Modelling the evolution of genetic instability during tumour progression. **2013**, 6, 20-33		35
1807	Preventive evolutionary medicine of cancers. **2013**, 6, 134-43		24
1806	Evolutionary foundations for cancer biology. **2013**, 6, 144-59		124
1805	High-throughput sequencing of the melanoma genome. **2013**, 22, 10-7		31
1804	Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model. **2013**, 1, 6		19
1803	Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. **2013**, 34, 610-8		10
1802	Comprehensive genome sequencing of the liver cancer genome. **2013**, 340, 234-40		45
1801	The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. **2013**, 34, 849-62		40
1800	Translating genomics to the clinic: implications of cancer heterogeneity. **2013**, 59, 127-37		20
1799	Surgery for NSCLC in the era of personalized medicine. **2013**, 10, 235-44		75
1798	The implications of clonal genome evolution for cancer medicine. *New England Journal of Medicine*, **2013**, 368, 842-51	59.2	275
1797	Translating metastasis-related biomarkers to the clinic--progress and pitfalls. **2013**, 10, 169-79		35
1796	Kidney cancer in 2012: new frontiers in kidney cancer research. **2013**, 10, 70-2		3

1795	Emerging targeted agents in metastatic breast cancer. **2013**, 10, 191-210	138
1794	Resistance to BRAF-targeted therapy in melanoma. **2013**, 49, 1297-304	273
1793	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. **2013**, 13, 365-76	191
1792	Interplay between the cancer genome and epigenome. **2013**, 153, 38-55	588
1791	Lessons from the cancer genome. **2013**, 153, 17-37	912
1790	Imaging mass spectrometry-based molecular histology differentiates microscopically identical and heterogeneous tumors. **2013**, 12, 1847-55	18
1789	Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. **2013**, 98, E934-42	45
1788	Metastasis awakening: the challenges of targeting minimal residual cancer. **2013**, 19, 274-5	45
1787	Evolution and dynamics of pancreatic cancer progression. **2013**, 32, 5253-60	131
1786	Individualized therapy for metastatic colorectal cancer. **2013**, 274, 1-24	19
1785	Human cancer regression antigens. **2013**, 25, 284-90	29
1784	The war on cancer: are we winning?. **2013**, 34, 1275-84	36
1783	Cancer genome-sequencing study design. **2013**, 14, 321-32	85
1782	The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. **2013**, 31, 1383-8	8
1781	Advances for studying clonal evolution in cancer. **2013**, 340, 212-9	60
1780	The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS□**2013**, 153, 590-600	395
1779	Revisiting Mutagenesis in the Age of High-Throughput Sequencing. **2013**, 257-270	
1778	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. **2013**, 497, 108-12	1220

1777	Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. **2013**, 15, 234-47	163
1776	Implementing personalized cancer genomics in clinical trials. **2013**, 12, 358-69	231
1775	Cell sorting in cancer research--diminishing degree of cell heterogeneity. **2013**, 1836, 105-22	12
1774	Proteomic analysis of frozen tissue samples using laser capture microdissection. **2013**, 1002, 71-83	20
1773	RET inhibition: implications in cancer therapy. **2013**, 17, 403-19	36
1772	Mitochondrial complex II, a novel target for anti-cancer agents. **2013**, 1827, 552-64	78
1771	Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. **2013**, 39, 592-601	96
1770	Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. **2013**, 59, 75-84	10
1769	Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. **2013**, 108, 2088-96	33
1768	Identification of driver mutations in lung cancer: first step in personalized cancer. **2013**, 8, 3-14	20
1767	(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. **2013**, 49, 395-402	32
1766	Towards more effective advanced drug delivery systems. **2013**, 454, 496-511	107
1765	Melanoma immunotherapy: historical precedents, recent successes and future prospects. **2013**, 5, 169-82	24
1764	Taxane benefit in breast cancer--a role for grade and chromosomal stability. **2013**, 10, 357-64	30
1763	Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. **2013**, 108, 901-7	192
1762	Leading malignant cells initiate collective epithelial cell invasion in a three-dimensional heterotypic tumor spheroid model. **2013**, 30, 615-30	100
1761	Cancer karyotypes: survival of the fittest. **2013**, 3, 148	42
1760	Cells of origin for cancer: an updated view from prostate cancer. **2013**, 32, 3655-63	49

1759	Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. **2013**, 21, 1507-16	29
1758	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. **2013**, 93, 252-9	177
1757	Ex vivo culture of human prostate tissue and drug development. **2013**, 10, 483-7	96
1756	mTOR inhibitors in advanced breast cancer: ready for prime time?. **2013**, 39, 742-52	22
1755	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. **2013**, 58, 346-52	48
1754	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. **2013**, 125, 659-69	201
1753	High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. **2013**, 25, 2897-902	131
1752	Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. **2013**, 108, 2164-71	77
1751	Replication stress links structural and numerical cancer chromosomal instability. **2013**, 494, 492-496	521
1750	Adapting clinical paradigms to the challenges of cancer clonal evolution. **2013**, 182, 1962-71	36
1749	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. **2013**, 10, 377-89	146
1748	Pharmacogenomics in Cancer Therapeutics. **2013**, 89-116	
1747	Vemurafenib in melanoma. **2013**, 13, 513-22	8
1746	Do mutator mutations fuel tumorigenesis?. **2013**, 32, 353-61	44
1745	Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. **2013**, 21, 580-4	262
1744	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. **2013**, 14, 777-86	237
1743	Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. **2013**, 230, 174-83	31
1742	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. **2013**, 13, 697-709	12

1741	Acquired resistance to crizotinib from a mutation in CD74-ROS1. *New England Journal of Medicine*, **2013**, 368, 2395-401	59.2	268
1740	Parallel evolution of tumour subclones mimics diversity between tumours. **2013**, 230, 356-64		70
1739	Biopsies: next-generation biospecimens for tailoring therapy. **2013**, 10, 437-50		86
1738	Genetic heterogeneity in breast cancer: the road to personalized medicine?. **2013**, 11, 151		42
1737	Cancer heterogeneity: implications for targeted therapeutics. **2013**, 108, 479-85		549
1736	Predicting efficacy of cancer cell killing under hypoxic conditions with single cell DNA damage assay. **2013**, 85, 6953-7		10
1735	Integrated molecular analysis of clear-cell renal cell carcinoma. **2013**, 45, 860-7		723
1734	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. **2013**, 13, 486-96		44
1733	Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device. **2013**, 13, 340-8		77
1732	Mouse models for lung cancer. **2013**, 7, 165-77		95
1731	Development of a single-cell array for large-scale DNA fluorescence in situ hybridization. **2013**, 13, 1316-24		13
1730	Personalized medicine in oncology: where have we come from and where are we going?. **2013**, 14, 931-9		36
1729	A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. **2013**, 189, 1930-8		52
1728	Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. **2013**, 8, 486-93		43
1727	[,]Iodometomidate imaging in adrenocortical carcinoma. **2013**, 98, 2755-64		33
1726	Translational utility of next-generation sequencing. **2013**, 102, 137-9		29
1725	Cancer networks and beyond: interpreting mutations using the human interactome and protein structure. **2013**, 23, 219-26		19
1724	Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells. **2013**, 74, 138-147		5

1723	Comparative analysis of mathematical models of cell death and thermal damage processes. **2013**, 29, 262-80	92
1722	First steps in experimental cancer evolution. **2013**, 6, 535-48	20
1721	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. **2013**, 15, 415-53	340
1720	Optimal management of metastatic renal cell carcinoma: current status. **2013**, 73, 427-38	84
1719	Pathological concordance and surgical outcomes of sporadic synchronous unilateral multifocal renal masses treated with partial nephrectomy. **2013**, 189, 43-7	21
1718	Tumor-derived microvesicles: the metastasomes. **2013**, 80, 75-82	19
1717	Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. **2013**, 288, 27343-27357	127
1716	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. **2013**, 20, R83-99	215
1715	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. **2013**, 137, 828-60	365
1714	High-throughput gene expression and mutation profiling: current methods and future perspectives. **2013**, 8, 401-6	11
1713	Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment. **2013**, 66, 319-25	28
1712	Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. **2013**, 109, 2833-41	74
1711	Current readings: the most influential and recent studies regarding resection of lung cancer in m1a disease. **2013**, 25, 251-5	8
1710	Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. **2013**, 31, 3898-905	52
1709	From human genome to cancer genome: the first decade. **2013**, 23, 1054-62	103
1708	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). **2013**, 130, 31-7	14
1707	Tumour heterogeneity in the clinic. **2013**, 501, 355-64	770
1706	Building a personalized medicine infrastructure at a major cancer center. **2013**, 31, 1849-57	85

1705	Comprehensive molecular characterization of clear cell renal cell carcinoma. **2013**, 499, 43-9	2184
1704	Molekulare Bildgebung und pathologische Diagnostik. **2013**, 19, 809-820	
1703	Rolle und Aufgaben der chirurgischen Onkologie im Rahmen molekular definierter Therapien. **2013**, 19, 858-862	
1702	Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. **2013**, 13, 827-44	84
1701	Designing transformative clinical trials in the cancer genome era. **2013**, 31, 1834-41	135
1700	Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. **2013**, 59, 211-24	373
1699	Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. **2013**, 132, E106-15	21
1698	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. **2013**, 8, 823-59	632
1697	Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). **2013**, 8, 1409-16	20
1696	Lung adenocarcinoma with ipsilateral breast metastasis: a simple coincidence?. **2013**, 8, 974-9	16
1695	[Role of high-throughput sequencing in oncology]. **2013**, 100, 295-301	3
1694	[Explicative models of cancer biology: an enlarged vision]. **2013**, 100, 697-713	1
1693	Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. **2013**, 8, 293-9	13
1692	Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy. **2013**, 6, 433	4
1691	Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. **2013**, 20, 1059-66	48
1690	Takeda's Oncology Discovery Strategy. **2013**, 43, 357-61	2
1689	Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities. **2013**, 13, 358-367	
1688	8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. **2013**, 5, 339-57	11

1687 Meeting the challenges of PET-based molecular imaging in cancer. **2013**, 13, 671-80 1

1686 Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. **2013**, 19, 3914-24 43

1685 Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. **2013**, 14, 883-7 3

1684 Harnessing massively parallel DNA sequencing for the personalization of cancer management. **2013**, 10, 183-190 2

1683 5-hydroxymethylcytosine profiling as an indicator of cellular state. **2013**, 5, 655-69 46

1682 Chromothripsis: breakage-fusion-bridge over and over again. **2013**, 12, 2016-23 34

1681 Mobilizing and evaluating anticancer T cells: pitfalls and solutions. **2013**, 12, 1325-40 4

1680 Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy. **2013**, 269, 801-9 150

1679 Single-cell mutational profiling and clonal phylogeny in cancer. **2013**, 23, 2115-25 96

1678 Endobronchial ultrasound-guided transbronchial needle aspiration for lymphoma: the final frontier. **2013**, 188, 1183-5 2

1677 ADN tumoral circulant et cancer du sein m□tastatique : un biomarqueur d□venir ?. **2013**, 100, 935-936

1676 [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]. **2013**, 100, 1295-310 3

1675 Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses. **2013**, 10, 221-225 4

1674 Challenges and strategies for identifying biomarkers for colorectal cancer. **2013**, 2, 487-489 1

1673 Retreatment after secondary resistance or mixed response: a pilot study. **2013**, 85, 350-5 1

1672 [Models of oncogenesis: an endless world?]. **2013**, 100, 555-60

1671 Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. **2014**, 127, 788-800 58

1670 Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. **2013**, 110, 18250-5 377

1669	Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. **2013**, 13, 559-67	4
1668	Brain neoplasms and coagulation. **2013**, 39, 881-95	27
1667	Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. **2013**, 3, 197	29
1666	EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. **2013**, 14, 24549-59	32
1665	An evolutionary perspective on anti-tumor immunity. **2012**, 2, 202	12
1664	When Medicine Meets Engineering-Paradigm Shifts in Diagnostics and Therapeutics. **2013**, 3, 126-54	4
1663	Biomolecular events in cancer revealed by attractor metagenes. **2013**, 9, e1002920	78
1662	NSAIDs modulate clonal evolution in Barrett's esophagus. **2013**, 9, e1003553	53
1661	Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. **2013**, 31, e401-3	23
1660	Tumor evolution in space: the effects of competition colonization tradeoffs on tumor invasion dynamics. **2013**, 3, 45	30
1659	Biological and clinical implications of cancer stem cells in primary brain tumors. **2013**, 3, 6	10
1658	Phylogenetic analysis of multiprobe fluorescence in situ hybridization data from tumor cell populations. **2013**, 29, i189-98	37
1657	Collaborating to conquer cancer: lessons from our children. **2013**, 31, 825-32	3
1656	Discordance in ER‐PR and HER2 receptor status across different distant breast cancer metastases within the same patient. **2013**, 24, 3017-23	34
1655	Going with the flow: from circulating tumor cells to DNA. **2013**, 5, 207ps14	90
1654	Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. **2013**, 14, 1405-17	12
1653	ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. **2013**, 73, 1233-40	16
1652	Pathology and genetics of uveal melanoma. **2013**, 45, 18-27	23

1651 Bibliography. Head and neck. Current world literature. **2013**, 25, 325-30

1650 Integrated genomic, transcriptomic, and RNA-interference analysis of genes in somatic copy number gains in pancreatic ductal adenocarcinoma. **2013**, 42, 1016-26 3

1649 Renal cell carcinoma: trying but failing to improve the only curative therapy. **2013**, 36, 459-61 2

1648 Metastatic mechanisms in follicular cell-derived thyroid cancer. **2013**, 20, R307-19 32

1647 Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology. **2013**, 8, 765-71 30

1646 PBRM1 and BAP1 as novel targets for renal cell carcinoma. **2013**, 19, 324-32 77

1645 Personalized medicine for metastatic breast cancer. **2013**, 25, 615-24 4

1644 Biomarker-driven patient selection for early clinical trials. **2013**, 25, 305-12 30

1643 Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. **2013**, 3, 20130010 41

1642 Exploiting ecological principles to better understand cancer progression and treatment. **2013**, 3, 20130020 66

1641 A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. **2013**, 10, 20130011 34

1640 Evolution of intratumoral phenotypic heterogeneity: the role of trait inheritance. **2013**, 3, 20130016 28

1639 Targeted therapies of solid cancers: new options, new challenges. **2013**, 25, 296-304 17

1638 Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. **2013**, 14, 699-702 4

1637 From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes: A Personal History. **2013**, 2, 1-86

1636 Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. **2013**, 19, 1411-21 41

1635 Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors. **2013**, 54, 1931-7 25

1634 Dynamic and nuclear expression of PDGFR and IGF-1R in alveolar Rhabdomyosarcoma. **2013**, 11, 1303-13 24

1633	Next-Generation Sequencing & Molecular Diagnostics. **2013**,	1
1632	Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma. **2013**, 15, 818-28	22
1631	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). **2013**, 19, 4868-78	145
1630	Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. **2013**, 93, 236-8	4
1629	Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. **2013**, 110, 12426-31	44
1628	A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. **2013**, 19, 1612-9	18
1627	Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. **2013**, 3, 908-21	29
1626	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. **2013**, 105, 960-7	112
1625	[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. **2013**, 12, 819-28	12
1624	The impact of molecular targets in cancer drug development: major hurdles and future strategies. **2013**, 6, 23-34	14
1623	Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority. **2013**, 31, 3312-4	7
1622	Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography. **2013**, 58, 187-203	72
1621	Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine. **2013**, 1, 1000124	17
1620	Are companion diagnostics useful?. **2013**, 59, 198-201	11
1619	Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. **2013**, 73, 3275-84	45
1618	Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. **2013**, 19, 4058-66	58
1617	Lessons learned from radiation oncology clinical trials. **2013**, 19, 6089-100	24
1616	Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. **2013**, 258, 678-88; discussion 688-9	45

1615	Precise inference of copy number alterations in tumor samples from SNP arrays. **2013**, 29, 2964-70	9
1614	Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo. **2013**, 110, 9025-30	67
1613	Circulating tumour cells: insights into tumour heterogeneity. **2013**, 274, 137-43	37
1612	(4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. **2013**, 54, 117-23	50
1611	Rapid screening of novel agents for combination therapy in sarcomas. **2013**, 2013, 365723	12
1610	Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. **2013**, 13, 385-94	19
1609	Cellular potts modeling of tumor growth, tumor invasion, and tumor evolution. **2013**, 3, 87	108
1608	Immunogene Zelltodmarker HMGB1 und sRAGE als neue prädiktive und prognostische Serum Biomarker bei Tumorerkrankungen/Immunogenic cell death markers HMGB1 and sRAGE as new predictive and prognostic serum biomarkers in cancer disease. **2013**, 37,	1
1607	Multi-field-of-view framework for distinguishing tumor grade in ER+ breast cancer from entire histopathology slides. **2013**, 60, 2089-99	75
1606	Cytogenomics and gene expression in a case of metachronous bilateral renal cell carcinomas with drop metastasis: Resolving a diagnostic dilemma with molecular technologies. **2013**, 63, 326-32	2
1605	Human tissue in systems medicine. **2013**, 280, 5949-56	8
1604	Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development. **2013**, 229, 502-14	15
1603	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. **2013**, 26, 646-53	35
1602	Differential expression of STAT1 and IFN-□in primary and invasive or metastatic wilms tumors. **2013**, 108, 152-6	3
1601	PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. **2013**, 2, 496-506	40
1600	TrAp: a tree approach for fingerprinting subclonal tumor composition. **2013**, 41, e165	90
1599	Complexity in cancer biology: is systems biology the answer?. **2013**, 2, 164-77	26
1598	Inhibiting the RAS-PI3K pathway in cancer therapy. **2013**, 34 Pt. B, 107-36	16

1597	Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. **2013**, 231, 424-32		83
1596	Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. **2013**, 26, 708-22		10
1595	Inference of tumor phylogenies with improved somatic mutation discovery. **2013**, 20, 933-44		40
1594	A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. **2013**, 19, 6787-801		63
1593	Mutations in critical domains confer the human mTOR gene strong tumorigenicity. **2013**, 288, 6511-21		32
1592	Tivantinib in hepatocellular carcinoma. **2013**, 22, 141-7		21
1591	Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. **2013**, 19, 691-8		105
1590	New strategies in prostate cancer: translating genomics into the clinic. **2013**, 19, 517-23		47
1589	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. **2013**, 31, 131-61		35
1588	Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. **2013**, 19, 4315-25		27
1587	CHOP THERAPY INDUCED MITOCHONDRIAL REDOX STATE ALTERATION IN NON-HODGKIN'S LYMPHOMA XENOGRAFTS. **2013**, 6, 1350011		7
1586	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. **2013**, 6, 381-95		28
1585	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. **2013**, 10, 1700-13		29
1584	Acquired resistance to crizotinib from a mutation in CD74-ROS1. *New England Journal of Medicine*, **2013**, 369, 1173	59.2	36
1583	Genome evolution during progression to breast cancer. **2013**, 23, 1097-108		86
1582	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. **2013**, 108, 2426-32		50
1581	Return of the malingering mutants. **2013**, 109, 1391-3		3
1580	Support vector machine-based nomogram predicts postoperative distant metastasis for patients with oesophageal squamous cell carcinoma. **2013**, 109, 1109-16		20

1579	Genomic medicine frontier in human solid tumors: prospects and challenges. **2013**, 31, 1874-84	90
1578	Three different brain tumours evolving from a common origin. **2013**, 2, e41	7
1577	Diagnostic perspectives in the epoch of next-generation sequencing. **2013**, 98-111	
1576	Circulating tumor cells as prognostic markers in neuroendocrine tumors. **2013**, 31, 365-72	121
1575	Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?. **2013**, 18, 651-2	3
1574	Incorporating genomics into breast cancer clinical trials and care. **2013**, 19, 6371-9	14
1573	Genomic heterogeneity of translocation renal cell carcinoma. **2013**, 19, 4673-84	61
1572	A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. **2013**, 12, 809-18	41
1571	MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. **2013**, 11, 1112-21	28
1570	From the Cover: Neutralization of terminal differentiation in gliomagenesis. **2013**, 110, 14520-7	50
1569	Performance characteristics of the MammaPrint breast cancer diagnostic gene signature. **2013**, 10, 801-811	20
1568	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. **2013**, 27, 1462-72	50
1567	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. **2013**, 3, 3494	38
1566	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. **2013**, 231, 21-34	292
1565	Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature. **2013**, 36, 348-56	13
1564	Will we cure cancer by sequencing thousands of genomes?. **2013**, 6, 57	2
1563	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. **2013**, 15, R97	13
1562	Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. **2013**, 5, 1741-1743	9

1561	EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. **2013**, 11, 1040-4	30
1560	The breast cancer overdiagnosis conundrum: an oncologist's viewpoint. **2013**, 158, 60-1	5
1559	The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers. **2013**,	5
1558	Chemically induced rat Schwann cell neoplasia as a model for early-stage human peripheral nerve sheath tumors: phenotypic characteristics and dysregulated gene expression. **2013**, 72, 404-15	3
1557	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. **2013**, 2013, 300-301	1
1556	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. **2013**, 8, 346-51	240
1555	Response. **2013**, 144, 715-716	
1554	Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis. **2013**, 38, 453-5	10
1553	[Translational research - towards personalized medicine]. **2013**, 141, 122-5	
1552	Candidate cancer-targeting agents identified by expression-profiling arrays. **2013**, 6, 447-58	3
1551	DNA Damage, DNA Repair and Cancer. **2013**,	26
1550	Changing concepts of cancer stem cells and their application into targeted therapy for cancer. **2013**, 56, 611	1
1549	In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. **2013**, 4, 2407-18	38
1548	Myeloma: a subclonal disease?. **2013**, 19, 383-387	
1547	[Discrepancies between primary tumor and metastasis: impact on personalized medicine]. **2013**, 100, 561-8	6
1546	miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. **2013**, 8, e54398	97
1545	A robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH. **2013**, 8, e67031	36
1544	Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. **2013**, 8, e70346	28

1543	The role of chromosome missegregation in cancer development: a theoretical approach using agent-based modelling. **2013**, 8, e72206	8
1542	RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer. **2013**, 8, e72820	17
1541	Next-generation sequence analysis of cancer xenograft models. **2013**, 8, e74432	23
1540	A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. **2013**, 8, e76438	27
1539	Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer. **2013**, 8, e77825	8
1538	Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. **2013**, 8, e78343	21
1537	Niche-dependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations. **2013**, 8, e83651	17
1536	Quantifying tumour heterogeneity with CT. **2013**, 13, 140-9	235
1535	Clonal evolution and therapeutic resistance in solid tumors. **2013**, 4, 2	14
1534	Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. **2013**, 4, 21	129
1533	Cisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells. **2013**, 4, 163	5
1532	Next-generation sequencing of disseminated tumor cells. **2013**, 3, 320	29
1531	"Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?. **2013**, 3, 124-43	14
1530	Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma. **2013**, 1, 240-253	3
1529	Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. **2013**, 4, 1868-81	64
1528	The application of high-throughput analyses to cancer diagnosis and prognosis. 46-51	
1527	BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. **2013**, 4, 310-5	117
1526	Imprint. **2013**, 8, 299-299	

1525	Analysis. **2013**, 129-144	
1524	Autologous Immunotherapy as a Novel Treatment for Bladder Cancer. **2013**,	
1523	Cancer Genes and Chromosome Instability. **2013**,	4
1522	Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. **2013**, 118-25	18
1521	Molecular profiling and the reclassification of cancer: divide and conquer. **2013**, 127-34	20
1520	Gastrointestinal Polyposis Syndromes: Early Tumor Evolution Through the Looking Glass. **2014**, 1319-1331	
1519	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. **2014**, 7, 1689-704	54
1518	Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. **2014**, 9, e88401	27
1517	Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent. **2014**, 9, e86833	19
1516	Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy?. **2014**, 9, e88598	38
1515	Estimating dose painting effects in radiotherapy: a mathematical model. **2014**, 9, e89380	42
1514	Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. **2014**, 9, e99590	13
1513	Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. **2014**, 9, e101777	109
1512	Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis. **2014**, 9, e107105	13
1511	In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA. **2014**, 9, e107927	12
1510	Correlation between plasma DNA and tumor status in an animal model. **2014**, 9, e111881	14
1509	Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. **2014**, 9, e115510	55
1508	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. **2014**, 5, 12383-97	134

1507	Comparison of outcomes between women with de novo stage IV and relapsed breast cancer. **2014**, 81, 139-47	10
1506	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. **2014**, 5, 166-72	116
1505	Exome sequencing: what clinicians need to know. **2014**, 15	3
1504	Epithelial-mesenchymal transition in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma. **2014**, 32, 2673-9	12
1503	Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma. **2014**, 7, 645-54	6
1502	Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. **2014**, 11	
1501	Molecular Biology of Non-small-cell Lung Cancer. **2014**, 34, 4	2
1500	Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins. **2014**, 7, 1705-16	16
1499	[Hypotheses for the genesis of cancer: a historical perspective]. **2014**, 30, 679-82	0
1498	Insights into the next generation of cancer stem cell research. **2014**, 19, 1015-27	6
1497	Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. **2014**, 8, E832-40	4
1496	Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. **2014**, 5, 2107-15	18
1495	CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. **2014**, 5, 6191-205	9
1494	Prospects of Omics Based Molecular Approaches in Colorectal Cancer Diagnosis and Treatment in the Developing World: A Case Study in Cape Town, South Africa. **2014**,	1
1493	Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization. **2014**, 93, e81	2
1492	4. Der virtuelle Patient Systembiologie als Chance f eine individualisierte Medizin.	
1491	The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?. **2014**, e5-10	3
1490	Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. **2014**, 10, 52-63	70

1489	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. **2014**, 11, 545-558	6
1488	Personalized Cancer Therapy. **2014**, 671-824	1
1487	Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease. **2014**, 3, 367-376	2
1486	EGFR mutation testing practice in advanced non-small cell lung cancer. **2014**, 192, 759-63	5
1485	Unraveling the clonal hierarchy of somatic genomic aberrations. **2014**, 15, 439	61
1484	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. **2014**, 10, 380-394	1
1483	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. **2014**, 15, 473	52
1482	DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. **2014**, 12, 235	35
1481	Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma. **2014**, 35, 12361-8	8
1480	Empirical prediction of genomic susceptibilities for multiple cancer classes. **2014**, 111, 1921-6	5
1479	Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. **2014**, 8, 629-32	4
1478	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. **2014**, 15, 454	224
1477	Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. **2014**, 15, 530	49
1476	Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models. **2014**, 148, 501-10	9
1475	Mosaike in der Tumorzytogenetik. **2014**, 26, 324-329	
1474	Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors. **2014**, 87, 83-94	4
1473	A framework for generalized subspace pattern mining in high-dimensional datasets. **2014**, 15, 355	2
1472	Tumor suppressor VHL functions in the control of mitotic fidelity. **2014**, 74, 2422-31	21

1471	Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. **2014**, 111, E866-75	96
1470	The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. **2014**, 16, 937-41	19
1469	SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. **2014**, 15, 443	47
1468	Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. **2014**, 14, 115	31
1467	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. **2014**, 12, 277	10
1466	89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. **2014**, 20, 3945-54	83
1465	Satellite DNA transcripts in blood plasma as potential markers of tumor growth. **2014**, 48, 878-885	6
1464	Postzygotic single-nucleotide mosaicisms in whole-genome sequences of clinically unremarkable individuals. **2014**, 24, 1311-27	39
1463	Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. **2014**, 110, 616-24	24
1462	Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. **2014**, 9, 1848-59	44
1461	Material witness: No substitute. **2014**, 13, 124	
1460	Targeting oncogenic drivers. **2014**, 41, 1-14	6
1459	Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging. **2014**, 20, 1348-53	100
1458	Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. **2014**, 33, 440-8	7
1457	Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays. **2014**, 5, 5662	36
1456	Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. **2014**, 20, 2607-2616	20
1455	Circulating Tumor Cells: Who is the Killer?. **2014**, 7, 161-76	26
1454	A combinatorial approach for analyzing intra-tumor heterogeneity from high-throughput sequencing data. **2014**, 30, i78-86	78

1453	Clinically relevant cancer biomarkers and pharmacogenetic assays. **2014**, 20, 65-72	11
1452	The confounding effects of tumour heterogeneity and cellular plasticity on personalized surgical management of colorectal cancer. **2014**, 16, 329-31	2
1451	Application of artificial neural network and multiple linear regression models for predicting survival time of patients with non-small cell cancer using multiple prognostic factors including FDG-PET measurements. **2014**,	1
1450	The Molecular Biology of Neurofibromatosis Type 1. **2014**, 3, 1-79	
1449	Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. **2014**, 15, 1771-1790	44
1448	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. **2014**, 24, 743-50	440
1447	Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair. **2014**, 5, 11-20	2
1446	A genetic model for gallbladder carcinogenesis and its dissemination. **2014**, 25, 1086-97	40
1445	SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. **2014**, 10, e1003665	301
1444	Current opportunities and challenges of magnetic resonance spectroscopy, positron emission tomography, and mass spectrometry imaging for mapping cancer metabolism in vivo. **2014**, 2014, 625095	20
1443	Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. **2014**, 4, 123	116
1442	Vaccines against Cancer. **2014**,	
1441	Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma. **2014**, 16, 1028-35	14
1440	Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology. **2014**, 134, 1389-1396	2
1439	Pulmonary metastasectomy and the use of molecular and radiological markers: is this a way to reduce unavailing surgery?. **2014**, 45, 417-8	1
1438	Brain Tumor Genomics. **2014**, 321-338	
1437	Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics. **2014**, 10, e1003740	41
1436	The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. **2014**, 13, 329-40	57

1435	Deterministic Mathematical Modelling for Cancer Chronotherapeutics: Cell Population Dynamics and Treatment Optimization. **2014**, 265-294	1
1434	Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. **2014**, 12, e1001906	136
1433	Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. **2014**, 4, 13	12
1432	Phylogenetic quantification of intra-tumour heterogeneity. **2014**, 10, e1003535	91
1431	Inferring clonal composition from multiple sections of a breast cancer. **2014**, 10, e1003703	84
1430	Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. **2014**, 10, e1004462	94
1429	Report from the OECI Oncology Days 2014. **2014**, 8, 496	3
1428	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. **2014**, 138, 241-56	738
1427	Genetic basis of thrombosis in cancer. **2014**, 40, 284-95	15
1426	Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?. **2014**, 106, dju042	11
1425	Targeted therapy for renal cell carcinoma: The next lap. **2014**, 13, 3	21
1424	Repopulation of tumor cells during fractionated radiotherapy and detection methods (Review). **2014**, 7, 1755-1760	21
1423	Next-generation sequencing in clinical oncology: next steps towards clinical validation. **2014**, 6, 2296-312	41
1422	Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. **2014**, 5, 162	42
1421	Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. **2014**, 4, 142	42
1420	Emerging understanding of multiscale tumor heterogeneity. **2014**, 4, 366	73
1419	Non-invasive molecular profiling of cancer using photoacoustic imaging of functionalized gold nanorods. **2014**,	1
1418	How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts?. **2014**, 30, 261-8	0

1417	The relationship between delay period eye movements and visuospatial memory. **2014**, 14,	47
1416	Tumor heterogeneity-based resistance guides personalized cancer medicine. **2014**, 10, 1889-92	4
1415	A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. **2014**, 3, 1493-501	11
1414	Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?. **2014**, 10, 417-28	16
1413	Improving productivity of modern-day drug discovery. **2014**, 9, 115-8	8
1412	The biggest challenges currently facing companion diagnostic advancement. **2014**, 14, 27-35	5
1411	Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. **2014**, 13, 307-315	34
1410	Hitting the bull's eye: targeting HMGA1 in cancer stem cells. **2014**, 14, 23-30	14
1409	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. **2014**, 24, 1881-93	218
1408	Location, location, location: The relationship of anatomic site, antigen expression, and T-cell infiltration in human melanoma metastases. **2014**, 3, e28963	2
1407	SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. **2014**, 7, 2006-18	280
1406	Intravital imaging of mouse colonic adenoma using MMP-based molecular probes with multi-channel fluorescence endoscopy. **2014**, 5, 1677-89	22
1405	EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. **2014**, 4, 956-71	199
1404	New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use. **2014**, 134, 2523-33	27
1403	Molecular and cellular heterogeneity: the hallmark of glioblastoma. **2014**, 37, E11	110
1402	Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. **2014**, 59, 924-34	31
1401	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. **2014**, 111, 828-36	33
1400	Oncogenic Ras stimulates Eiger/TNF exocytosis to promote growth. **2014**, 141, 4729-39	12

1399	Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. **2014**, 270, 464-71		190
1398	Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. **2014**, 13, 986-95		38
1397	Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. **2014**, 33, 402-16		10
1396	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. **2014**, 63, 1700-10		296
1395	Personalized oncology: genomic screening in phase 1. **2014**, 122, 723-33		16
1394	Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. **2014**, 64, 484-93		13
1393	Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. **2014**, 32, 4050-8		79
1392	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. **2014**, 27, 1612-20		59
1391	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. **2014**, 128, 615-27		29
1390	Cancer-drug discovery--let's get ready for the next period. *New England Journal of Medicine*, **2014**, 371, 2227-8	59.2	6
1389	Gene co-expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines. **2014**, 135, 2795-803		21
1388	DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. **2014**, 20, 814-26		35
1387	Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer. **2014** , 233, 425-35		43
1386	NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention. **2014**, 135, 1832-41		31
1385	The structural basis for mTOR function. **2014**, 36, 91-101		35
1384	Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. **2014**, 190, 1117-26		114
1383	Molecular and genetic diversity in the metastatic process of melanoma. **2014**, 233, 39-50		47
1382	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. **2014**, 111, 17606-11		46

1381	Multidisciplinary urological engagement in translational renal cancer research. **2014**, 114, 474-5	2
1380	Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. **2014**, 4, 175-185	247
1379	The evolving genomic classification of lung cancer. **2014**, 232, 121-33	74
1378	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. **2014**, 44, 1011-22	46
1377	Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression. **2014**, 21, 891-902	19
1376	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. **2014**, 101, 925-38	30
1375	Management of metastatic kidney cancer in the era of personalized medicine. **2014**, 51, 85-97	4
1374	A systematic review of the role of hepatectomy in the management of metastatic renal cell carcinoma. **2014**, 40, 1622-8	4
1373	Altering the response to radiation: sensitizers and protectors. **2014**, 41, 848-59	25
1372	Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?. **2014**, 7, 941-51	113
1371	Prioritizing targets for precision cancer medicine. **2014**, 25, 2295-2303	106
1370	ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci. **2014**, 74, 1551-9	12
1369	MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. **2014**, 21, 2109-25	74
1368	Genetic relationship between multiple squamous cell carcinomas arising in the oral cavity. **2014**, 36, 94-100	13
1367	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. **2014**, 2, 1132-41	33
1366	Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. **2014**, 113, E157-63	47
1365	Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinoma. **2014**, 135, 78-87	29
1364	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. **2014**, 12, 111-8	90

1363	Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas. **2014**, 40, 736-46	9
1362	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. **2014**, 28, 513-26	7
1361	Therapeutic potential of midkine in cardiovascular disease. **2014**, 171, 936-44	25
1360	Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine?. **2014**,	14
1359	Evolving concepts of tumor heterogeneity. **2014**, 4, 69	49
1358	Statistical feature selection for enhanced detection of brain tumor. **2014**,	4
1357	Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. **2014**, 9, e115346	13
1356	Strategy of Daiichi Sankyo discovery research in oncology. **2014**, 44, 109-15	1
1355	A method for reproduction of metastases in the liver. **2014**, 157, 773-5	10
1354	Population dynamics inside cancer biomass driven by repeated hypoxia-reoxygenation cycles. **2014**, 2, 85-99	7
1353	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. **2014**, 14, 638	20
1352	Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. **2014**, 14, 786	25
1351	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. **2014**, 14, 982	21
1350	New concepts in breast cancer genomics and genetics. **2014**, 16, 460	23
1349	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. **2014**, 15, 433	53
1348	Deep sequencing of the X chromosome reveals the proliferation history of colorectal adenomas. **2014**, 15, 437	0
1347	Polygenic in vivo validation of cancer mutations using transposons. **2014**, 15, 455	3
1346	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. **2014**, 15, 470	9

1345	TIDE: Inter-chromosomal translocation and insertion detection using embeddings. **2014**,	3
1344	Investigational therapies targeting the ErbB family in oesophagogastric cancer. **2014**, 23, 1349-63	3
1343	Diagnostic utility of targeted next-generation sequencing in problematic cases. **2014**, 38, 534-41	15
1342	RET mutation and expression in small-cell lung cancer. **2014**, 9, 1316-23	37
1341	Highly multiplexed phenotypic imaging for cell proliferation studies. **2014**, 19, 145-57	13
1340	Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer. **2014**, 49, 116-23	16
1339	Evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT. **2014**, 35, 446-52	25
1338	BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. **2014**, 46, 311-5	8
1337	The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma. **2014**, 8, 258-64	13
1336	Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. **2014**, 38, 502-9	26
1335	In times of crisis, go liquid!. **2014**, 26, 440	
1334	Cancer stem cells: a systems biology view of their role in prognosis and therapy. **2014**, 25, 353-67	29
1333	Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?. **2014**, 9, 7-17	30
1332	A 'complex solution' to a 'complex' problem: tackling the complexity of cancer with botanicals. **2014**, 23, 568-78	6
1331	Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. **2014**, 26, 340-6	17
1330	Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?. **2014** , 25, 375-84	5
1329	The journey toward personalized cancer therapy. **2014**, 21, 36-43	3
1328	Ras in digestive oncology: from molecular biology to clinical implications. **2014**, 26, 454-61	11

1327	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. **2014**, 20, 272-80	14
1326	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. **2014**, 6, 224ra26	203
1325	Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. **2014**, 20, 1721-3	2
1324	High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer. **2014**, 74, 4983-95	19
1323	Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. **2014**, 66, 936-48	109
1322	Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. **2014**, 6, 231ra49	38
1321	Adjuvant therapy for renal cell carcinoma: past, present, and future. **2014**, 19, 851-9	47
1320	First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. **2014**, 20, 5908-17	31
1319	Oncotype dx results in multiple primary breast cancers. **2014**, 8, 1-6	14
1318	NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. **2014**, 7, 556-69	60
1317	A phylogenetic model for understanding the effect of gene duplication on cancer progression. **2014**, 42, 2870-8	7
1316	Simultaneous genomic identification and profiling of a single cell using semiconductor-based next generation sequencing. **2014**, 3, 70-7	
1315	Pathology of Pediatric Gastrointestinal and Liver Disease. **2014**,	5
1314	Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. **2014**, 4, 78	60
1313	Extracranial oligometastatic renal cell carcinoma: current management and future directions. **2014**, 10, 761-74	22
1312	Regulation of Mitochondrial Function by MicroRNA. **2014**, 59-80	
1311	Spatial and temporal cancer evolution: causes and consequences of tumour diversity. **2014**, 14 Suppl 6, s33-7	14
1310	Drug-delivery considerations in oncology. **2014**, 6-19	

1309	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. **2014**, 20, 1955-64	173
1308	Epidermal growth factor mutation as a diagnostic and therapeutic target in metastatic poorly differentiated thyroid carcinoma: a case report and review of the literature. **2014**, 7, 393-400	8
1307	Brain neoplasms and coagulation-lessons from heterogeneity. **2014**, 5, e0030	8
1306	Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. **2014**, 20, 4263-75	30
1305	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. **2014**, 4, 194	18
1304	Drug-diagnostics co-development in oncology. **2014**, 4, 208	4
1303	Glioblastoma multiforme: a look inside its heterogeneous nature. **2014**, 6, 226-39	136
1302	Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. **2014**, 12, 136-51	9
1301	Bespoke treatment: drivers beware!. **2014**, 10, 378-80	1
1300	Using high-density DNA methylation arrays to profile copy number alterations. **2014**, 15, R30	79
1299	Association between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer. **2014**, 93, e153	5
1298	Multiplex quantitative measurement of mRNAs from fixed tissue microarray sections. **2014**, 22, 323-30	1
1297	Cancer evolution: the final frontier of precision medicine?. **2014**, 25, 549-551	22
1296	Field cancerization in the colon: a role for aberrant DNA methylation?. **2014**, 2, 16-20	37
1295	The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. **2014**, 219, 158-65	28
1294	MicroRNAs as regulators of mitochondrial function: role in cancer suppression. **2014**, 1840, 1441-53	53
1293	Individualizing breast cancer treatment-The dawn of personalized medicine. **2014**, 320, 1-11	24
1292	A personalized view on cancer immunotherapy. **2014**, 352, 113-25	45

1291	The fall and rise of pharmacology--(re-)defining the discipline?. **2014**, 87, 4-24	23
1290	[Molecular profiling of non-small cell lung cancer]. **2014**, 70, 47-62	2
1289	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. **2014**, 6, 377-87	186
1288	The nature of change. **2014**, 11, 464-70	3
1287	Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. **2014**, 42, 457-63	15
1286	Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. **2014**, 25, 379-92	273
1285	Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. **2014**, 6, 514-27	194
1284	Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan. **2014**, 763-764, 45-52	5
1283	Acquired resistance to EGFR-targeted therapies in colorectal cancer. **2014**, 8, 1084-94	94
1282	New insights and challenges in mismatch repair: getting over the chromatin hurdle. **2014**, 19, 48-54	31
1281	Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. **2014**, 7, 5-13	68
1280	Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma. **2014**, 32, 601-6	14
1279	Personalizing therapy for colorectal cancer. **2014**, 12, 139-44	21
1278	Les méthodes de séquençage de « nouvelle génération » (NGS) et le cancer broncho-pulmonaire: principales technologies, applications et limites actuelles en pathologie. **2014**, 2014, 51-58	
1277	Perspective, the one most responsive to change. **2014**, 41, 297-8	10
1276	Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. **2014**, 87, 150-61	224
1275	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. **2014**, 28, 384-390	202
1274	Glioblastoma: from molecular pathology to targeted treatment. **2014**, 9, 1-25	346

1273	Miniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cells. **2014**, 14, 14-23	56
1272	Clonal evolution in hematological malignancies and therapeutic implications. **2014**, 28, 34-43	120
1271	Colorectal cancer defeating? Challenge accepted!. **2014**, 39, 61-81	13
1270	The '-omics' revolution and oesophageal adenocarcinoma. **2014**, 11, 19-27	25
1269	DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. **2014**, 81, 25-35	30
1268	Application of Translational Science to Clinical Development. **2014**, 1-21	
1267	Do targeted agents offer clinical benefit as presurgical therapy?. **2014**, 32, 3-8	7
1266	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. **2014**, 32, 19-29	10
1265	Characterizing solid renal neoplasms with MRI in adults. **2014**, 39, 358-87	27
1264	Shifting focus in optical image-guided cancer therapy. **2014**, 16, 1-9	19
1263	Preclinical studies on tumor-specific fluorescent targeting agents: the need for a gold standard of tumor localization. **2014**, 16, 10-2	3
1262	The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. **2014**, 31, 111-34	14
1261	Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. **2014**, 116, 413-9	30
1260	Normoxic or hypoxic CD44/CD41 aBIntegrin-positive prostate PC3 cell side fractions and cancer stem cells. **2014**, 31, 779	3
1259	Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. **2014**, 31, 810	13
1258	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. **2014**, 33, 295-307	3
1257	Collagen as a double-edged sword in tumor progression. **2014**, 35, 2871-82	321
1256	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. **2014**, 33, 321-31	21

1255	Genetic alterations and personalized medicine in melanoma: progress and future prospects. **2014**, 106, djt435	57
1254	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. **2014**, 46, 225-233	866
1253	Challenges facing the development of cancer vaccines. **2014**, 1139, 543-53	5
1252	Functional Imaging in Oncology. **2014**,	1
1251	Tumor heterogeneity confounds and illuminates: assessing the implications. **2014**, 20, 342-4	82
1250	Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. **2014**, 20, 344-6	51
1249	Evolution of the cancer stem cell model. **2014**, 14, 275-91	1462
1248	Miniaturized pre-clinical cancer models as research and diagnostic tools. **2014**, 69-70, 52-66	34
1247	Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. **2014**, 66, 874-80	92
1246	Tumor evolution in response to chemotherapy: phenotype versus genotype. **2014**, 6, 417-9	40
1245	Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma. **2014**, 16, 401	21
1244	Inferring clonal evolution of tumors from single nucleotide somatic mutations. **2014**, 15, 35	163
1243	Clinical application of circulating tumor cells in breast cancer. **2014**, 37, 9-15	38
1242	Biomarkers in renal cancer. **2014**, 464, 359-65	21
1241	Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice. **2014**, 464, 257-63	21
1240	NRAS mutations in primary and metastatic melanomas of Japanese patients. **2014**, 19, 544-8	21
1239	Contributions from emerging transcriptomics technologies and computational strategies for drug discovery. **2014**, 32, 1316-9	5
1238	Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. **2014**, 28, 1705-15	162

1237	Precision treatment for cancer: role of prognostic and predictive markers. **2014**, 51, 30-45	22
1236	Second-Generation Sequencing for Cancer Genome Analysis. **2014**, 13-30	1
1235	BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. **2014**, 45, 935-41	19
1234	Historical Perspective and Current Challenges of Cancer Genomics. **2014**, 3-10	
1233	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. **2014**, 25, 91-101	657
1232	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. **2014**, 65, 577-84	166
1231	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. **2014**, 32, 479-84	434
1230	Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis. **2014**, 35, 4125-32	14
1229	Entering the era of single-cell transcriptomics in biology and medicine. **2014**, 11, 22-4	169
1228	Trends in cancer-targeted antibody-drug conjugates. **2014**, 9, 1-8	6
1227	Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. **2014**, 156, 1298-1311	191
1226	The challenge of intratumour heterogeneity in precision medicine. **2014**, 276, 41-51	50
1225	"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. **2014**, 133, 624-31	197
1224	The colon cancer stem cell microenvironment holds keys to future cancer therapy. **2014**, 18, 1040-8	28
1223	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. **2014**, 123, 3414-9	51
1222	Emerging technologies in extracellular vesicle-based molecular diagnostics. **2014**, 14, 307-21	98
1221	Hypermutable DNA chronicles the evolution of human colon cancer. **2014**, 111, E1889-98	25
1220	Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. **2014**, 16, 343-9	35

1219	Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. **2014**, 16, 75-88	87
1218	Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. **2014**, 65, 713-20	54
1217	Reply to J□he Verine, Christophe Leboeuf and Philippe Ratajczak's letter to the editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol 2013;64:689-91. **2014**, 65, e71-2	
1216	Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. **2014**, 50, 517-24	20
1215	Molecular Testing in Cancer. **2014**,	1
1214	Mouse tumour models to guide drug development and identify resistance mechanisms. **2014**, 232, 103-11	24
1213	The Significance of Transcriptome Sequencing in Personalized Cancer Medicine. **2014**, 49-64	1
1212	Prostate Cancer Genomics as a Driver of Personalized Medicine. **2014**, 233-245	1
1211	Intratumoral heterogeneity in kidney cancer. **2014**, 46, 214-5	35
1210	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. **2014**, 20, 682-8	406
1209	Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. **2014**, 25, 151-64	35
1208	Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. **2014**, 20, 2898-909	116
1207	Metastatic progression of breast cancer: insights from 50 years of autopsies. **2014**, 232, 23-31	112
1206	Implications of intratumour heterogeneity for treatment stratification. **2014**, 232, 264-73	52
1205	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. **2014**, 232, 274-82	40
1204	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. **2014**, 111, E672-81	59
1203	Simply better glycoproteins. **2014**, 32, 443-5	24
1202	Cancer biomarker discovery: current status and future perspectives. **2014**, 90, 659-77	76

1201	Tumor signatures in the blood. **2014**, 32, 441-3	82
1200	Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. **2014**, 23, 53-60	32
1199	MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. **2014**, 14, 924-35	62
1198	Addressing overdiagnosis and overtreatment in cancer: a prescription for change. **2014**, 15, e234-42	313
1197	Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. **2014**, 5, 3802	25
1196	Update: the status of clinical trials with kinase inhibitors in thyroid cancer. **2014**, 99, 1543-55	23
1195	Circulating tumor cells: a multifunctional biomarker. **2014**, 20, 2553-68	151
1194	Circulating tumour cells--a bona fide cause of metastatic cancer. **2014**, 33, 747-56	25
1193	ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. **2014**, 66, 77-84	169
1192	DNA sequencing of cancer: what have we learned?. **2014**, 65, 63-79	37
1191	Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. **2014**, 24, 200-11	58
1190	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. **2014**, 1845, 31-41	54
1189	Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. **2014**, 46, 24-32	92
1188	Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. **2014**, 53, 38-51	99
1187	Colon resection: is standard technique adequate?. **2014**, 23, 25-34	4
1186	Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. **2014**, 14, 24-31	25
1185	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. **2014**, 24, 241-50	124
1184	Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. **2014**, 89, 207-16	124

1183	Breast Cancer. **2014**,	3
1182	Cancer imaging: Lighting up tumours. **2014**, 13, 122-4	32
1181	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. **2014**, 5, 2997	564
1180	Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage. **2014**, 343, 437-440	116
1179	Clonal analysis via barcoding reveals diverse growth and differentiation of transplanted mouse and human mammary stem cells. **2014**, 14, 253-63	46
1178	Just caring: assessing the ethical and economic costs of personalized medicine. **2014**, 32, 202-6	18
1177	Liquid biopsies: genotyping circulating tumor DNA. **2014**, 32, 579-86	1419
1176	Molecular analysis of circulating tumour cells-biology and biomarkers. **2014**, 11, 129-44	446
1175	Genomic sequencing for cancer diagnosis and therapy. **2014**, 65, 33-48	30
1174	Biobanking 3.0: evidence based and customer focused biobanking. **2014**, 47, 300-8	78
1173	Addressing genetic tumor heterogeneity through computationally predictive combination therapy. **2014**, 4, 166-74	73
1172	The evolution of the unstable cancer genome. **2014**, 24, 61-7	52
1171	Bias from removing read duplication in ultra-deep sequencing experiments. **2014**, 30, 1073-1080	30
1170	Molecularly targeted cancer therapy: some lessons from the past decade. **2014**, 35, 41-50	206
1169	Treatment of HER2-positive breast cancer. **2014**, 23, 128-136	134
1168	Single-cell RNA-seq reveals dynamic, random monoallelic gene expression in mammalian cells. **2014**, 343, 193-6	816
1167	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. **2014**, 343, 189-193	912
1166	Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. **2014**, 107, 373-404	34

1165	Biomarkers of renal cell carcinoma. **2014**, 32, 243-51	34
1164	Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. **2014**, 4, 80-93	700
1163	Precision medicine for metastatic renal cell carcinoma. **2014**, 32, 5-15	14
1162	In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. **2014**, 69-70, 205-216	55
1161	Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. **2014**, 111, E4726-35	123
1160	Gene Expression Profiling in Pancreatic Cancer. **2014**, 151-167	
1159	Tumor heterogeneity in the clinic: is it a real problem?. **2014**, 6, 43-51	63
1158	Sunitinib re-challenge in advanced renal-cell carcinoma. **2014**, 111, 1047-53	31
1157	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. **2014**, 14, 1023-31	1
1156	Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma. **2014**, 64, 847-62	12
1155	Molecular biomarkers in advanced renal cell carcinoma. **2014**, 20, 2060-71	57
1154	[Radionuclide therapy of endocrine-related cancer]. **2014**, 54, 1007-15	1
1153	Invasive breast cancer: stratification of histological grade by gene-based assays: a still relevant example from an older data set. **2014**, 65, 429-33	27
1152	Intratumor mapping of intracellular water lifetime: metabolic images of breast cancer?. **2014**, 27, 760-73	53
1151	Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. **2014**, 13, 4581-93	28
1150	Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly. **2014**, 16, 401	7
1149	Renal cell carcinoma. **2014**, 349, g4797	311
1148	The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. **2014**, 74, 873-83	66

1147	Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. **2014**, 111, 16538-43	97
1146	Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. **2014**, 50, 2916-24	27
1145	A filter-flow perspective of haematogenous metastasis offers a non-genetic paradigm for personalised cancer therapy. **2014**, 50, 3068-75	14
1144	Mathematical Oncology 2013. **2014**,	1
1143	Identification of functional cooperative mutations of SETD2 in human acute leukemia. **2014**, 46, 287-93	173
1142	Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. **2014**, 25, 959-67	40
1141	Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma. **2014**, 60, 1314-26	40
1140	Mitochondria in cancer: why mitochondria are a good target for cancer therapy. **2014**, 127, 211-27	25
1139	Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. **2014** , 5, 4006	2330
1138	The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning. **2014**, 87, 20140369	66
1137	Metabolomic profiling of tumor-bearing mice. **2014**, 543, 275-96	4
1136	Detecting ultralow-frequency mutations by Duplex Sequencing. **2014**, 9, 2586-606	247
1135	Immunomodulation in cancer. **2014**, 17, 17-21	24
1134	Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. **2014**, 23, 1553-62	13
1133	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. **2014**, 6, 5	127
1132	The translation of cancer genomics: time for a revolution in clinical cancer care. **2014**, 6, 22	10
1131	The promise of circulating tumor cell analysis in cancer management. **2014**, 15, 448	38
1130	Cancer genomics: one cell at a time. **2014**, 15, 452	202

1129	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. **2014**, 15, 453	139
1128	Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. **2014**, 25, 2304-2313	115
1127	MicroRNAs: Key Regulators of Oncogenesis. **2014**,	10
1126	Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes. **2014**, 11, 705-719	4
1125	Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. **2014**, 74, 7181-4	45
1124	Breast cancer intra-tumor heterogeneity. **2014**, 16, 210	188
1123	Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. **2014** , 32, 991-6	7
1122	Anticancer Genes. **2014**,	1
1121	Reconstructing Mutational History in Multiply Sampled Tumors Using Perfect Phylogeny Mixtures. **2014**, 354-367	10
1120	Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. **2014**, 136, 5647-55	378
1119	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. **2014**, 25, 1959-1965	181
1118	Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. **2014**, 353, 167-75	42
1117	Patient-derived xenograft models: an emerging platform for translational cancer research. **2014**, 4, 998-1013	1018
1116	Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. **2014**, 55, 337-48	17
1115	Tracking cellular and immune therapies in cancer. **2014**, 124, 257-96	24
1114	Synthesis and evaluation of the cytotoxic activity of 1,2-furanonaphthoquinones tethered to 1,2,3-1H-triazoles in myeloid and lymphoid leukemia cell lines. **2014**, 84, 708-17	36
1113	Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. **2014**, 111, 1663-72	48
1112	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. **2014**, 111, 8838-43	85

1111	Recently targeted kinases and their inhibitors-the path to clinical trials. **2014**, 17, 58-63	45
1110	Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. **2014**, 20, 331-43	45
1109	Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?. **2014**, 14, 853-69	19
1108	Translational genomics and head and neck cancer: toward precision medicine. **2014**, 86, 412-21	17
1107	Evolutionary game theory: cells as players. **2014**, 10, 3044-65	77
1106	Current status of molecular biomarkers in endometrial cancer. **2014**, 16, 403	45
1105	On-chip separation and analysis of RNA and DNA from single cells. **2014**, 86, 1953-7	43
1104	Translating genomics for precision cancer medicine. **2014**, 15, 395-415	56
1103	Prognostic impact of [18F]fluorodeoxyglucose positron emission tomography scanning in the era of molecular oncology. **2014**, 32, 1630	1
1102	ASPECCT: panitumumab versus cetuximab for colorectal cancer. **2014**, 15, e302-3	
1101	Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma. **2014**, 465, 321-30	12
1100	Digital pathology and image analysis in tissue biomarker research. **2014**, 70, 59-73	120
1099	Fructose-1,6-bisphosphatase opposes renal carcinoma progression. **2014**, 513, 251-5	323
1098	Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. **2014**, 32, 877-84	9
1097	Regulation of alternative splicing of CD44 in cancer. **2014**, 26, 2234-9	114
1096	Biomonitoring exposures to carcinogens. **2014**, 785-798	3
1095	Design and applications of bispecific heterodimers: molecular imaging and beyond. **2014**, 11, 1750-61	22
1094	New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. **2014**, 20, 4425-35	21

1093	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. **2014**, 120, 1059-67	100
1092	The somatic genomic landscape of chromophobe renal cell carcinoma. **2014**, 26, 319-330	521
1091	Genomics of pancreatic ductal adenocarcinoma. **2014**, 13, 381-5	2
1090	Mutation, clonal fitness and field change in epithelial carcinogenesis. **2014**, 234, 296-301	11
1089	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. **2014**, 165, 441-54	77
1088	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. **2014**, 13, 1690-704	239
1087	Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. **2014**, 8, 798-806	177
1086	Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. **2014**, 36, 827-35	42
1085	Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. **2014**, 104, 234-41	46
1084	Multimodal molecular imaging of integrin □□3 for in vivo detection of pancreatic cancer. **2014**, 55, 446-51	36
1083	An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. **2014**, 87, 20130753	32
1082	Clinical translation of molecular imaging agents used in PET studies of cancer. **2014**, 124, 329-74	5
1081	Advances in kinase targeting: current clinical use and clinical trials. **2014**, 35, 604-20	150
1080	Precision therapy for lymphoma--current state and future directions. **2014**, 11, 585-96	55
1079	Intratumor heterogeneity alters most effective drugs in designed combinations. **2014**, 111, 10773-8	70
1078	CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers. **2014**, 14, 673-82	65
1077	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. **2014**, 346, 256-9	659
1076	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. **2014**, 46, 699-724	23

1075	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. **2014**, 4, 1269-80	326
1074	Is target validation all we need?. **2014**, 17, 81-6	4
1073	Prognosis prediction and staging. **2014**, 28, 855-65	15
1072	TGF and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. **2014**, 20, 6429-38	80
1071	FaSD-somatic: a fast and accurate somatic SNV detection algorithm for cancer genome sequencing data. **2014**, 30, 2498-500	15
1070	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. **2014**, 20, 4827-36	150
1069	Pathology-validated PET image data sets and their role in PET segmentation. **2014**, 2, 253-267	12
1068	The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. **2014**, 14, 390	22
1067	Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. **2014**, 14, 456	81
1066	The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies. **2014**, 14, 595	12
1065	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. **2014**, 12, 140	30
1064	Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. **2014**, 15, 420	22
1063	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. **2014**, 4, 554-63	279
1062	Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. **2014**, 514, 54-8	397
1061	Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. **2014**, 465, 339-50	34
1060	American association for cancer research AACR congress 2014. **2014**, 16, 341-366	
1059	Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. **2014**, 31, 735-48	53
1058	Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. **2014**, 111, 17-24	57

1057	Integration of genomic information in the clinical management of HCC. **2014**, 28, 831-42	19
1056	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. **2014**, 14, 398-402	13
1055	Diagnostic performance of shear wave elastography of the breast according to scanning orientation. **2014**, 33, 1797-804	6
1054	Cancer: evolution within a lifetime. **2014**, 48, 215-36	146
1053	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. **2014**, 346, 251-6	752
1052	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. **2014**, 92, 709-22	64
1051	Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. **2014**, 38, 1353-61	54
1050	Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. **2014**, 74, 1-13	15
1049	Tumour heterogeneity and the evolution of polyclonal drug resistance. **2014**, 8, 1095-111	275
1048	Amorphous regions-of-interest projection method for simplified longitudinal comparison of dynamic regions in cancer imaging. **2014**, 61, 264-72	1
1047	Where cancer genomics should go next: a clinician's perspective. **2014**, 23, R69-75	12
1046	HIV-1-induced AIDS in monkeys. **2014**, 344, 1401-5	61
1045	Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. **2014**, 20, 2476-84	118
1044	MTOR mutations in the crosshairs of targeted therapy. **2014**, 4, 513-5	2
1043	Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. **2014**, 45, 1092-9	47
1042	Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. **2014**, 191, 479-86	43
1041	A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. **2014**, 110, 2178-86	22
1040	Expanding the computational toolbox for mining cancer genomes. **2014**, 15, 556-70	146

1039	Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. **2014**, 24, 1256-66	62
1038	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. **2014**, 20, 5064-74	1661
1037	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. **2014**, 20, 4613-24	171
1036	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. **2014**, 25, 1729-1735	258
1035	Report on the International Workshop 'Cancer stem cells: the mechanisms of radioresistance and biomarker discovery'. **2014**, 90, 607-14	3
1034	Breast cancer redox heterogeneity detectable with chemical exchange saturation transfer (CEST) MRI. **2014**, 16, 670-9	24
1033	Tumor antigen discovery through translation of the cancer genome. **2014**, 58, 292-9	8
1032	Cancer research: a hurdle race. **2014**, 79, 385-90	4
1031	Direct observation of genomic heterogeneity through local haplotyping analysis. **2014**, 15, 418	1
1030	Vascular measurements correlate with estrogen receptor status. **2014**, 14, 279	35
1029	Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. **2014**, 13, 39	26
1028	Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationships. **2014**, 8, 9	4
1027	Data integration in the era of omics: current and future challenges. **2014**, 8 Suppl 2, I1	230
1026	Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. **2014**, 7, 30	51
1025	Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. **2014** , 27, 869-74	19
1024	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. **2014**, 25, 1756-1761	91
1023	Modern Cancer Drug Discovery. **2014**, 3-53	5
1022	Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. **2014**, 35, 329-40	57

1021	Advances in the approach to novel drug clinical development for breast cancer. **2014**, 9, 647-68	5
1020	PyClone: statistical inference of clonal population structure in cancer. **2014**, 11, 396-8	584
1019	Brain tumor cells in circulation are enriched for mesenchymal gene expression. **2014**, 4, 1299-309	159
1018	Views of primary care providers regarding the return of genome sequencing incidental findings. **2014**, 86, 461-8	24
1017	Translational research in oncology--10 years of progress and future prospects. **2014**, 11, 649-62	51
1016	Understanding lung cancer molecular subtypes. **2014**, 11, 441-453	1
1015	Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. **2014**, 4, 186-99	74
1014	Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. **2014**, 91, 135-43	129
1013	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. **2014**, 4, 546-53	224
1012	Current concepts on the molecular pathology of non-small cell lung carcinoma. **2014**, 31, 306-13	31
1011	Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. **2014**, 13, 2846-55	28
1010	Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. **2014**, 30, 3532-40	95
1009	Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer. **2014**, 7, 613-9	17
1008	Algorithms in Bioinformatics. **2014**,	3
1007	Influence of biospecimen variables on proteomic biomarkers in breast cancer. **2014**, 20, 3870-83	41
1006	Animal models of gastrointestinal and liver diseases. New mouse models for studying dietary prevention of colorectal cancer. **2014**, 307, G249-59	7
1005	Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. **2014**, 40, 1192-8	40
1004	Low enhancement on multiphase contrast-enhanced CT images: an independent predictor of the presence of high tumor grade of clear cell renal cell carcinoma. **2014**, 203, W295-300	45

1003	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). **2014**, 15, 267-74	282
1002	Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. **2014**, 25, 366-78	79
1001	Single cell analysis of cancer genomes. **2014**, 24, 82-91	99
1000	Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma. **2014**, 74, 3157-67	18
999	The molecular biology of renal cancer: another piece of the puzzle. **2014**, 66, 85-6	4
998	Next-generation sequencing of urologic cancers: next is now. **2014**, 66, 4-7	7
997	The potential of hyperpolarized (13)C MRI in assessing signaling pathways in cancer. **2014**, 21, 215-22	10
996	Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. **2014**, 66, 956-63	31
995	Molecular testing in oncology: problems, pitfalls and progress. **2014**, 83, 309-15	21
994	Just so stories: the random acts of anti-cancer nanomedicine performance. **2014**, 10, 1661-6	57
993	Current readings: management of N2 disease for lung cancer. **2014**, 26, 67-70	2
992	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. **2014**, 23, 473-81	10
991	Pancreatectomy for metastatic disease: a systematic review. **2014**, 40, 379-86	49
990	Transcriptional coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes. **2014**, 8, 1306-25	16
989	Carcinoma-associated fibroblasts provide operational flexibility in metastasis. **2014**, 25, 33-46	91
988	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2□**2014**, 50, 1531-40	25
987	Monitoring of tumor response to Cisplatin using optical spectroscopy. **2014**, 7, 230-9	14
986	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. **2014**, 8, 150-8	34

985	Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice. **2014**, 111, 475-81	9
984	Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. **2014**, 85, 19-24	162
983	Personalized medicine: present and future of breast cancer management. **2014**, 91, 223-33	40
982	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. **2014**, 46, 837-843	240
981	Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling. **2014**, 119, 243-51	2
980	Patient-derived xenografts for individualized care in advanced sarcoma. **2014**, 120, 2006-15	118
979	Molecular Mechanisms of Angiogenesis. **2014**,	3
978	The epigenetic sole of sex and dosage compensation. **2014**, 46, 215-7	9
977	Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union. **2014**, 20, 1458-68	33
976	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. **2014**, 344, 1396-401	2401
975	The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. **2014**, 87, 20140065	28
974	Molecular genetics of clear-cell renal cell carcinoma. **2014**, 32, 1968-76	213
973	Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. **2014**, 54, 716-27	583
972	Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. **2014**, 4, 348-61	115
971	High-definition reconstruction of clonal composition in cancer. **2014**, 7, 1740-1752	135
970	Classification of endometrial carcinoma: more than two types. **2014**, 15, e268-78	338
969	Mitochondria: The Anti- cancer Target for the Third Millennium. **2014**,	2
968	Textural Parameters of Tumor Heterogeneity in ‚Ê-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer. **2014**, 55, 891-7	114

967	Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. **2014**, 108, 843-52	13
966	Reading between the lines; understanding drug response in the post genomic era. **2014**, 8, 1112-9	10
965	Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma. **2014**, 207, 206-13	8
964	Mechanisms of buffer therapy resistance. **2014**, 16, 354-64.e1-3	19
963	Sequential combination of karyotyping and RNA-sequencing in the search for cancer-specific fusion genes. **2014**, 53, 462-5	14
962	Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. **2014**, 92, 218-26	10
961	Brain metastasis: new opportunities to tackle therapeutic resistance. **2014**, 8, 1120-31	28
960	Tetraspanin-enriched microdomains and hepatocellular carcinoma progression. **2014**, 351, 23-9	15
959	Oncogenes in melanoma: an update. **2014**, 93, 1-10	45
958	BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. **2014**, 191, 603-10	58
957	Genomics and transcriptomics in drug discovery. **2014**, 19, 126-32	51
956	Nodal metastasis microRNA expression correlates with the primary tumour in MTC. **2014**, 84, 235-9	16
955	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. **2014**, 27, 4-18	191
954	An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. **2014**, 20, 3927-37	59
953	Cancer biomarkers: Written in blood. **2014**, 511, 524-6	107
952	Molecular profiling of single circulating tumor cells with diagnostic intention. **2014**, 6, 1371-86	182
951	Fluorescence-Guided Surgery: A Promising Approach for Future Oncologic Surgery. **2014**, 301-333	1
950	Theoretical and Experimental Foundations of the Cancer Stem Cell Model. **2014**, 1-16	1

949	The emerging quest for the optimal angiostatic combination therapy. **2014**, 42, 1608-15	17
948	Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: a case report. **2014**, 9, e43-6	5
947	Biology of cancer. **2014**, 25-43	
946	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. **2014**, 3, 1485-92	95
945	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. **2014**, 390-405	
944	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. **2014**, 12, 1629-49	12
943	Cellular imaging and texture analysis distinguish differences in cellular dynamics in mouse brain tumors. **2014**, 71, 1531-41	5
942	The potential of genome-wide analyses to improve non-small-cell lung cancer care. **2014**, 3, 383-396	
941	Organism-level models: When mechanisms and statistics fail us. **2014**, 489, 012096	
940	The biological and clinical challenge of liver cancer heterogeneity. **2014**, 1, 349-353	26
939	Zielgerichtetes Vorgehen gegen onkogene Faktoren. **2015**, 2, 61-70	
938	Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report. **2015**, 9, 2239-2243	12
937	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). **2015**, 2, 1814-20	11
936	Understanding melanoma stem cells. **2015**, 2, 179-188	20
935	Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). **2015**, 1, 76-82	11
934	On comparing heterogeneity across biomarkers. **2015**, 87, 558-67	10
933	Breast cancer heterogeneity: parallel evolution or conscious uncoupling?. **2015**, 237, 1-3	2
932	Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. **2015**, 22, 888-97	23

931	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. **2015**, 278, 545-70	38
930	Targeted cellular ablation based on the morphology of malignant cells. **2015**, 5, 17157	61
929	Tumor Heterogeneity in Breast Cancer. **2015**, 22, 294-302	8
928	The isolation and characterization of CTC subsets related to breast cancer dormancy. **2015**, 5, 17533	77
927	Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform. **2015**, 5, 11464	13
926	Chromosomal Instability (CIN) in Cancer. **2015**, 1-9	7
925	Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. **2015**, 5, 13664	42
924	A Bayesian feature allocation model for tumor heterogeneity. **2015**, 9,	13
923	Renal Cell Carcinoma and Targeted Therapy. **2015**, 287-295	1
922	The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies. **2015**, 315-324	
921	Future Perspectives. **2015**, 361-370	
920	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. **2015**, 125, 492-8	44
919	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. **2015**, 126, 445-53	103
918	Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. **2015**, 4, 27522	165
917	In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index. **2015**, 5, 14118	21
916	A streamlined search technology for identification of synergistic drug combinations. **2015**, 5, 14508	60
915	Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. **2015**, 42, 6725-35	102
914	High efficiency vortex trapping of circulating tumor cells. **2015**, 9, 064116	45

913	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. **2015**, 4, 3	83
912	Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. **2015**, 7, 1153-65	40
911	Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms. **2015**, e52879	1
910	Targeting Breast Cancer Metastasis. **2015**, 9, 23-34	87
909	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. **2015**, 14, 19-31	48
908	Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. **2015**, 14, 83-93	10
907	Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?. **2015**, 31, 434-9	1
906	Endogenous antibodies for tumor detection. **2014**, 4, 5088	6
905	Advanced Applications of RNA Sequencing and Challenges. **2015**, 9, 29-46	126
904	An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology. **2015**, 14, 87-107	8
903	Current and emerging therapies for bone metastatic castration-resistant prostate cancer. **2015**, 22, 109-20	33
902	Evaluation of HER2 Protein Expression Using 2 New Monoclonal Antibodies. **2015**, 23, 355-63	
901	Clinical significance of intratumor heterogeneity for gynecological carcinoma. **2015**, 1, 14-17	2
900	[Novel biomarkers in renal cell carcinoma. Identification and functional characterization]. **2015**, 36 Suppl 2, 201-4	
899	Cell injury, retrodifferentiation and the cancer treatment paradox. **2015**, 36, 7365-74	1
898	Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. **2015**, 15, 983	11
897	Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma. **2015**, 15, 17	6
896	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. **2015**, 13, 217	30

895	Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma. **2015**, 1,	1
894	Predictive value of biodynamic imaging in determining response to chemotherapy in dogs with spontaneous non-Hodgkin's lymphomas: a preliminary study. **2015**, 1,	7
893	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. **2015**, 237, 363-78	72
892	Targeted Therapy for Cancer in the Genomic Era. **2015**, 21, 294-8	34
891	Combined ultra-low input mRNA and whole-genome sequencing of human embryonic stem cells. **2015**, 16, 925	4
890	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. **2015**, 8, 58	29
889	Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. **2015**, 13, 182	27
888	Fast and scalable inference of multi-sample cancer lineages. **2015**, 16, 91	127
887	A method for accurate spatial registration of PET images and histopathology slices. **2015**, 5, 64	2
886	NCI investment in nanotechnology: achievements and challenges for the future. **2015**, 7, 251-65	14
885	Molecular Technologies in the Clinical Diagnostic Laboratory. **2015**, 22, 142-51	
884	Special Technologies for Ex Vivo Analysis of Cancer. **2015**, 22, 226-31	4
883	Toward Personalized Guidelines in Bladder Cancer. **2015**, 13, 1458-60	1
882	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. **2015**, 56, 469-476	1
881	[Digital PCR compartmentalization II. Contribution for the quantitative detection of circulating tumor DNA]. **2015**, 31, 180-6	6
880	The evolution of carrying capacity in constrained and expanding tumour cell populations. **2015**, 12, 056001	18
879	Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis. **2015**, 42, 1421-30	37
878	KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. **2015**, 111, 1059-64	14

877	Many private mutations originate from the first few divisions of a human colorectal adenoma. **2015**, 237, 355-62	22
876	Intratumor heterogeneity and transcriptional profiling in glioblastoma: translational opportunities. **2015**, 10, 369-381	
875	Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. **2015**, 1346, 63-70	8
874	Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer. **2015**, 102, 1048-55	8
873	The role of cytoreductive surgery in the era of targeted agents. **2015**, 25, 374-80	3
872	Pathology to enhance precision medicine in oncology: lessons from landscape ecology. **2015**, 22, 267-72	22
871	Of art and science: is personalized medicine getting personal enough?. **2015**, 27, 349-50	1
870	Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. **2015**, 39, 1140-7	33
869	Quantitative Computed Tomography Imaging Biomarkers in the Diagnosis and Management of Lung Cancer. **2015**, 50, 571-83	36
868	Semiautomatic Analysis on Computed Tomography in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements. **2015**, 30, 290-9	2
867	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis. **2015**, 30, 300-7	8
866	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. **2015**, e291-7	4
865	Molecular heterogeneity in adjacent cells in triple-negative breast cancer. **2015**, 7, 231-7	10
864	New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers. **2015**, 9, 601	9
863	New and emerging factors in tumorigenesis: an overview. **2015**, 7, 225-39	24
862	Continuous representation of tumor microvessel density and detection of angiogenic hotspots in histological whole-slide images. **2015**, 6, 19163-76	38
861	Genetic Heterogeneity in Colorectal Cancer and its Clinical Implications. **2015**, 28, 370-5	9
860	Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. **2015**, 6, 14744-53	59

859	Epigenetic Reduction of DNA Repair in Progression to Cancer. **2015**,	
858	Genetic Mutations in Human Esophageal and Gastric Cardia Cancers Detected by Ampliseq Sequencing. **2015**, 3,	
857	Computational characterisation of cancer molecular profiles derived using next generation sequencing. **2015**, 19, A78-91	4
856	Targeting Cancer Stem Cells: Promises and Challenges. **2016**, 16, 38-58	28
855	An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. **2015**, 30, e73-80	5
854	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. **2015**, 6, 12809-21	77
853	Interpretation of a heterogeneous radiological response as tumor heterogeneity or a non-tumor diagnosis: A case report. **2015**, 10, 2953-2956	1
852	Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. **2015**, e175-82	38
851	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). **2015**, 3, 519-43	13
850	Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. **2015**, 4,	7
849	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM Platform. **2015**, 16, 28765-82	29
848	Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model. **2015**, 6, 309	6
847	Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. **2015**, 5, 149	42
846	Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. **2015**, 5, 170	21
845	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. **2015**, 5, 183	62
844	Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor. **2015**, 5, 236	14
843	Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. **2015**, 5, 219-53	38
842	Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma. **2015**, 11, 88-98	30

841	ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. **2015**, 6, 1079-86	9
840	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. **2015**, 5, 1456-72	72
839	Role of autophagy in the maintenance and function of cancer stem cells. **2015**, 59, 95-108	30
838	Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. **2015**, 8, 3289-96	21
837	Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney Cancer. **2015**, 10, e0134645	41
836	Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq. **2015**, 10, e0135817	45
835	Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. **2015**, 10, e0136133	211
834	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease. **2015**, 10, e0136407	76
833	Three Dimensional Culture of Human Renal Cell Carcinoma Organoids. **2015**, 10, e0136758	29
832	Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. **2015**, 10, e0137794	7
831	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. **2015**, 10, e0139267	28
830	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. **2015**, 10, e0140712	442
829	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. **2015**, 10, e0145176	22
828	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. **2015**, 6, 44781-93	85
827	Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential. **2015**, 2015, 618021	24
826	KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?. **2015**, 2015, 753903	18
825	Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. **2015**, 2015, 891045	22
824	Biology of renal tumour cancer stem cells applied in medicine. **2015**, 19, A44-51	12

823	Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma. **2015**, 2015, 648495	24
822	From mice to humans: developments in cancer immunoediting. **2015**, 125, 3338-46	188
821	The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. **2015**, 7, 2094-109	18
820	Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies. **2015**, e239-47	7
819	Quantitation of multiclonality in control and drug-treated tumour populations using high-throughput analysis of karyotypic heterogeneity. **2015**, 1, 025001	6
818	. **2015**,	2
817	Autoimmune response to PARP and BRCA1/BRCA2 in cancer. **2015**, 6, 11575-84	20
816	Achievements and challenges of molecular targeted therapy in melanoma. **2015**, 177-86	29
815	New challenges in clinical research on hepatocellular carcinoma. **2016**, 108, 485-93	11
814	Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment. **2015**, 9, 598	4
813	Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. **2014**, 7, 33-43	3
812	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. **2015**, 6, 26814-25	117
811	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. **2015**, 20, 357-71	4
810	The biology and treatment of oligometastatic cancer. **2015**, 6, 8491-524	171
809	Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives. **2015**, 10, 44-55	7
808	Signal transduction in cancer. **2015**, 5,	421
807	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. **2015**, 17, 1486-96	33
806	Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates. **2015**, 12, 1250-8	40

805	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. **2015**, 21, 795-801	557
804	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. **2015**, 34, 5699-708	114
803	Spatial genomic heterogeneity within localized, multifocal prostate cancer. **2015**, 47, 736-45	306
802	T cell exclusion, immune privilege, and the tumor microenvironment. **2015**, 348, 74-80	1156
801	Advances and applications of single-cell sequencing technologies. **2015**, 58, 598-609	341
800	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. **2015**, 78, 81-6	35
799	Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. **2015**, 15, 1097	24
798	Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity. **2015**, 21, 4461-72	129
797	The relevance of EMT in breast cancer metastasis: Correlation or causality?. **2015**, 589, 1577-87	143
796	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. **2015**, 12, 541-52	80
795	Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. **2015**, 112, 1725-32	174
794	The cancer cell map initiative: defining the hallmark networks of cancer. **2015**, 58, 690-8	89
793	Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. **2015**, 5, 10291	17
792	Approach to Very Small (2015, 204, 1182-9	24
791	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. **2015**, 12, 408-24	318
790	Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. **2015**, 274, 742-51	32
789	Malignant Glioma: Viewpoint Chemotherapy. **2015**, 279-293	
788	Significance of Single Cell Sequencing in Future Medicine. **2015**, 1-10	

787	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. **2015**, 33, 303-9	12
786	PI3K□inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways. **2015**, 5, 9465	34
785	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. **2015**, 130, 419-34	41
784	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. **2015**, 37, 764-82	360
783	Advances in measuring single-cell pharmacology in vivo. **2015**, 20, 1087-92	26
782	Molecular Determinants of Metastasis in Renal Cell Cancer: Tracking Down the Real Killer. **2015**, 194, 278-9	1
781	Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). **2015**, 9, 1737-43	32
780	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. **2015**, 16, 676-85	163
779	89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. **2015**, 56, 63-9	79
778	Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. **2015**, 15, 206	81
777	The impact of FGFR1 and FRS2□expression on sorafenib treatment in metastatic renal cell carcinoma. **2015**, 15, 304	13
776	Antibody positron emission tomography imaging in anticancer drug development. **2015**, 33, 1491-504	78
775	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. **2015**, 61, 974-82	129
774	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. **2015**, 3, 1158-64	205
773	Personalized Therapy of Cancer. **2015**, 199-381	1
772	Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis. **2015**, 21, 4451-60	22
771	Whole-genome characterization of chemoresistant ovarian cancer. **2015**, 521, 489-94	890
770	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. **2015**, 21, 4153-64	13

769	Identifying metastatic breast tumors using textural kinetic features of a contrast based habitat in DCE-MRI. **2015**,	3
768	Kidney Cancer. **2015**,	1
767	Percutaneous biopsy for risk stratification of renal masses. **2015**, 7, 265-74	24
766	Nano-plasmonic exosome diagnostics. **2015**, 15, 725-33	36
765	Present and future of personalized medicine in adult genitourinary tumors. **2015**, 11, 1381-8	5
764	Purification of LC/GC-MS based biomolecular expression profiles using a topic model. **2015**,	0
763	Carcinomes bronchiques non ˆpetites cellules (CBNPC) mŁastatiques, mutŠ ou ràrrangŠ : comment dŁterminer la cible ?. **2015**, 7, 476-496	1
762	How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. **2015**, 25, 358-66	28
761	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. **2015**, 15, 713	33
760	High sensitivity rare cell capturing biochip with separable microstructures. **2015**,	
759	Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer. **2015**, 4, 174-82	23
758	Non-autonomous overgrowth by oncogenic niche cells: Cellular cooperation and competition in tumorigenesis. **2015**, 106, 1651-8	23
757	A simplicial complex-based approach to unmixing tumor progression data. **2015**, 16, 254	8
756	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. **2015**, 15, 1631-44	39
755	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. **2015**, 15, 1605-29	21
754	High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. **2015**, 26, 1408-15	97
753	Clonally related uterine leiomyomas are common and display branched tumor evolution. **2015**, 24, 4407-16	14
752	CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population. **2015**, 4, 822-31	15

751 Genome management and mismanagement--cell-level opportunities and challenges of whole-genome duplication. **2015**, 29, 2405-19 18

750 In Situ Analysis of Small Populations of Adherent Mammalian Cells Using Laser Ablation Electrospray Ionization Mass Spectrometry in Transmission Geometry. **2015**, 87, 12130-6 25

749 RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. **2015**, 113, 1313-22 18

748 Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. **2015**, 6, 8839 416

747 Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. **2015**, 16, 127 181

746 High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. **2015**, 10, 778-783 92

745 Edge effects in game-theoretic dynamics of spatially structured tumours. **2015**, 12, 20150154 24

744 Role of Precision Medicine in Patients with CNS Metastasis. **2020**, 69-82

743 PET in the Diagnosis of Head and Neck Cancer. **2020**, 187-221

742 Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine. **2020**, 355-392 1

741 Selection-driven tumor evolution involving non-cell growth promotion leads to patterns of clonal expansion consistent with neutrality interpretation. 0

740 Biomarkers from Bench to Bedside and Back Back-Translation of Clinical Studies to Preclinical Models. **2020**, 307-331

739 Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents. **2020**, 35, 187-190

738 ClonArch: Visualizing the Spatial Clonal Architecture of Tumors.

737 Generalized mathematical model of cancer heterogeneity.

736 La biopsia lquida en el manejo del cncer: una nueva herramienta revolucionaria de la medicina de precisin, an con limitaciones. **2020**, 1,

735 MicroRNA-143 inhibits proliferation and migration of prostate cancer cells. **2020**, 1-7 1

734 Reconstructing tumor evolutionary histories and clone trees in polynomial-time with SubMARine.

733	A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts. **2020**, 8, e9045	
732	Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival.	
731	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. **2021**, 2195, 31-47	1
730	Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy. **2020**, 7, 20-25	2
729	Self-generated persistent random forces drive phase separation in growing tumors.	
728	Tissue dynamics spectroscopic imaging: functional imaging of heterogeneous cancer tissue. **2020**, 25,	3
727	Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies. **2021**, 13, 170	1
726	Combined model based on enhanced CT texture features in liver metastasis prediction of high-risk gastrointestinal stromal tumors. **2021**, 47, 85	0
725	Diving into the mechanism of action of tumor immunotherapies with intravital imaging. **2021**,	0
724	miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway. **2021**, 35, e24078	2
723	Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response. **2021**,	0
722	Epithelial-to-Mesenchymal Transition-Derived Heterogeneity in Head and Neck Squamous Cell Carcinomas. **2021**, 13,	0
721	Feline sarcomatoid renal cell carcinoma with peritoneal carcinomatosis and effusion. **2021**, 10406387211054826	6
720	SETD2 negatively regulates cell size through its catalytic activity and SRI domain.	
719	Single-Cell Technologies for Cancer Therapy. **2022**, 767-850	
718	Basic Biology of Brain Metastasis. **2020**, 19-35	
717	Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. **2020**, 11, 35	1
716	Sclonal architectures predict clinical outcome in colon adenocarcinoma. **2021**, 25, 1796-1800	1

715 OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. **2020**, 19, 119-125

714 Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology. 9, 37-68

713 Spatiotemporal Dynamics of Cancer Phenotypic Quasispecies Under Targeted Therapy. **2021**, 1-20

712 Incorporating Circulating Biomarkers into Clinical Trials. **2020**, 233-247

711 In vivodeuterated water labeling allows tumor visualization via deuterium magnetic resonance spectroscopic imaging of cholesterol. 1

710 Renal Cancer Including Molecular Characterization. **2020**, 551-559

709 A personalized medicine approach to drug repurposing for the treatment of breast cancer molecular subtypes. **2020**, 191-211

708 Operative Therapie des Nierenzellkarzinoms. **2020**, 137-155

707 Cancer Stem Cells and the Development of Cancer. **2020**, 151-192

706 Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy. **2020**, 1-15

705 Leptomeningeal Disease and the Role of Intrathecal Therapy. **2020**, 169-186 1

704 PET in Gastrointestinal, Pancreatic, and Liver Cancers. **2020**, 597-625

703 An Individualized Approach for Somatic Variant Discovery. **2020**, 2120, 11-36

702 Chemoprevention of Cancer: Past, Present, and Future. **2020**, 1-18 0

701 Future Therapies for Malignant Brainstem Tumors. **2020**, 347-392

700 Incorporating Precision Medicine into Phase I Clinical Trials. **2020**, 221-231

699 Nanomaterials: From Research to Personalized Medicine. **2020**, 1-10

698 Radiomics as Applied in Precision Medicine. **2020**, 193-207 1

697	Precision Medicine and the Institutional Review Board: Ethics and the Genome. **2020**, 20, 98-103	0
696	Mass spectrometry imaging in lipid and proteomic profiling: an emerging tool for cancer diagnosis. **2020**, 259-295	0
695	Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK. **2020**, 1,	
694	Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines.	2
693	Nano-Liquid Chromatography Mass Spectrometry-Based Molecular and Phenotypic Analysis at Single-Cell Resolution. **2020**, 68, 44-48	1
692	Agent-Based Modeling and Analysis of Cancer Evolution.	
691	Resection of symptomatic non-small cell lung cancer brain metastasis in the setting of multiple brain metastases. **2021**, 1-7	3
690	Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy. **2021**,	0
689	Wound-like tumor periphery in human breast cancer predicts a convergent drug nonresponse.	0
688	CDC6: A novel canine tumour biomarker detected in circulating extracellular vesicles. **2021**,	2
687	Marker-free coselection for successive rounds of prime editing in human cells.	0
686	Joint inference of repeated evolutionary trajectories and patterns of clonal exclusivity or co-occurrence from tumor mutation trees.	
685	Machine intelligence in non-invasive endocrine cancer diagnostics. **2021**,	6
684	Quantitative nuclear phenotype signatures predict nodal disease in oral squamous cell carcinoma. **2021**, 16, e0259529	
683	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. **2021**, 5,	0
682	Dynamical Analysis of Drug Efficacy and Mechanism of Action Using GFP Reporters. 316-353	
681	Cancer Drug Delivery. 52-95	
680	The current and future roles of genomics. 79-94	

679 Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. **2020**, 21, 11

678 Understanding the potential benefits of adaptive therapy for metastatic melanoma. 1

677 Many are called but few are chosen Multiple clonal origins greatly elevate the functional heterogeneity of tumors.

676 Whole-exome Sequencing Reveals Genetic Underpinnings of Tongue Carcinoma in Chinese Population. **2020**, 1-9

675 MYC, BCL2 and BCL6 co-localisation patterns at single-cell resolution underlie their prognostic significance in diffuse large B-cell lymphoma.

674 Tissue Dynamics Spectroscopic Imaging: Functional Imaging of Heterogeneous Cancer Tissue.

673 Shape of population interfaces as an indicator of mutational instability in coexisting cell populations. **2020**, 17, 066002

672 Single-cell Multi-omics reveal heterogeneity and metastasis potential in different liver cancer cell lines. 0

671 Fluorescent Antibody Multiplexing with Oligo-Based Combinatorial Labeling.

670 A Bayesian Nonparametric Model for Inferring Subclonal Populations from Structured DNA Sequencing Data.

669 Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST.

668 The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics.

667 Potential clinical application of free-circulating DNA from blood in renal cancer. **2020**, 16, 174-189

666 Spectrum of VHL mutations in clear cell renal cell carcinoma. **2020**, 7, 48-57

665 Current achievements and future perspectives with liquid biopsy. **2020**, 9, 3-9

664 Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives. **2020**, 20, 2190-2206 1

663 Deep learning to classify single-cell RNA sequencing in primary glioblastoma. **2020**,

662 The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. **2013**, 4, 264-84 17

661	PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. **2012**, 2, 458-74	39
660	Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. **2013**, 21 Suppl 1, S1-5	66
659	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. **2013**, 18, 623-5	16
658	Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy. **2013**, 6, 275-86	3
657	Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?. **2014**, 4, 304-11	9
656	Stability of preclinical models of aggressive renal cell carcinomas. **2014**, 7, 2950-62	5
655	Plasma tumor DNA: on your markers, get set, go!. **2014**, 2, 2	6
654	Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. **2015**, 8, 793-9	20
653	Is surgery still the best management option for early stage NSCLC?. **2014**, 3, 159-63	2
652	High-grade ovarian cancer secreting effective exosomes in tumor angiogenesis. **2015**, 8, 5062-70	41
651	Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. **2015**, 8, 5327-35	13
650	Low PBRM1 identifies tumor progression and poor prognosis in breast cancer. **2015**, 8, 9307-13	7
649	A case of gastric cancer with heterogeneous components of EB virus (+)/TP53 (+) and EB virus (-)/TP53 (-). **2015**, 8, 11766-71	3
648	Proposal of "cyclic therapy", a novel treatment strategy with targeted agents for advanced renal cell carcinoma. **2013**, 2, 324-7	
647	Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. **2016**, 6, 577-86	17
646	Towards the identification of tissue-based proxy biomarkers. **2016**, 2016, 75-83	1
645	Improving systemic breast cancer therapy: time to look beyond the primary tumour?. **2015**, 7, 251-256	2
644	The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. **2017**, 128, 298-307	56

643 The future of genome-based medicine. **2013**, 456-8

642 Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer. **2018**, 6, 43-54 4

641 [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines]. **2015**, 18, 475-80 5

640 [Advances in Liquid Biopsy and its Clinical Application in the Diagnosis ?and Treatment of Non-small Cell Lung Cancer]. **2016**, 19, 394-8 1

639 [Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer]. **2018**, 21, 594-599 0

638 Genomics of adult and pediatric solid tumors. **2018**, 8, 1356-1386 12

637 [Advances on Recognizing and Managing Tumor Heterogeneity]. **2018**, 21, 712-718 1

636 Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer. **2018**, 8, 2377-2386 5

635 Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. **2019**, 17, 94-104

634 Methylation Analysis of and in Circulating Cell-Free DNA for Detection of Gastric Cancer: A Validation Study. **2020**, 12, 99-106 2

633 Applications of radiomics in genitourinary tumors. **2020**, 10, 2293-2308 5

632 TRIP13 predicts poor prognosis in clear cell renal cell carcinoma. **2020**, 10, 2909-2918

631 Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis. **2021**, 21, 179

630 A heterogeneous cellular response to ionizing radiation revealed by single cell transcriptome sequencing. **2021**, 11, 513-529 1

629 Background, applications and challenges of radiogenomics in genitourinary tumor. **2021**, 11, 1936-1945

628 Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast Cancer. **2021**, 4, 87-96

627 What morphology can teach us about renal cell carcinoma clonal evolution. **2020**, 18, 68-76 0

626 Oligometastatic non-small cell lung cancer: Current management. **2021**, 7, 311-319 0

625	Sensitivity Limits for ELISA Measurements of Molecular Biomarker Concentrations. **2017**, 3,	1
624	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. **2021**, 11, 3628-3644	2
623	Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study. **2021**, 86, 55-60	1
622	Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. **2021**, 11, e2021169S	1
621	Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level by QM-FISH. **2021**,	2
620	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer. **2021**, 13,	3
619	The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA. **2021**,	1
618	Overview of radiomics in prostate imaging and future directions. **2021**, 20210539	0
617	Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy. **2021**,	
616	Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia. **2021**, 13,	0
615	Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer. **2022**, 23, 22	0
614	Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. **2021**, 13,	1
613	A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer. **2021**, 57,	
612	Resolving the difference between left-sided and right-sided colorectal cancer by single-cell sequencing. **2021**,	0
611	Random clonal expansion as a limiting factor in transplantable in vivo CRISPR/Cas9 screens.	1
610	Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.. **2021**,	1
609	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. **2021**, 10,	4
608	Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. **2021**, 12, 6522	2

607	Liquid biopsies in pediatric oncology: opportunities and obstacles. **2021**, 34,	0
606	Clinical importance of high-mannose, fucosylated and complex N-glycans in breast cancermetastasis. **2021**,	5
605	Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples. **2021**,	1
604	Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases. **2021**, 13,	0
603	Tools used to assay genomic instability in cancers and cancer meiomitosis. **2021**, 16, 159	1
602	Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy. **2021**,	2
601	Hodgkin Lymphoma: Recent Progress in Overall Management.	
600	Genomic Characterization of De Novo Metastatic Breast Cancer.. **2021**,	1
599	The biophysics of cancer: emerging insights from micro- and nanoscale tools.. **2022**, 2, 2100056	5
598	Theranostics of Hematologic Disorders. **2022**, 359-432	
597	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. **2021**, 12, 6655	1
596	A renal cell carcinoma tumorgraft platform to advance precision medicine. **2021**, 37, 110055	4
595	Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. **2021**, 14, 201	1
594	Evolution of metastasis: new tools and insights. **2021**,	1
593	Morphological Aspect of Gastric Carcinomas. **2022**, 149-173	
592	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. **2021**, 5, 99	1
591	Mammakarzinom: Intervention in der Axilla Was ist sinnvoll?.	
590	Genome-Wide Copy Number Variation of Circulating Cell-Free DNA As a Biomarker in Head and Neck Cancer Patients Treated With Immunotherapy.	

589	Role of Pathologist in Precision Molecular and Digital Image Analyses. **2021**, 183-195	
588	Novel technologies in cfDNA analysis and potential utility in clinic.. **2021**, 33, 708-718	0
587	Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.. **2022**, 10, 28	0
586	A Darwinian perspective on tumor immune evasion.. **2021**, 1877, 188671	0
585	Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.. **2022**,	0
584	Molekulare Diagnostik in der Pathologie: etablierte Marker und Innovationen. **2022**, 28, 95	
583	The Development of Single-Cell Metabolism and Its Role in Studying Cancer Emergent Properties.. **2021**, 11, 814085	1
582	Biomarker-Based Evaluation of Treatment Response and Surveillance of HPV-Associated Squamous Cell Carcinoma. 1	0
581	LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data. **2022**, 58, 101523	1
580	Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.. **2021**, 7, 100357	0
579	Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma.. **2021**, 16, 101321	0
578	Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.. **2021**, 7, 100305	0
577	NTRK point mutations and their functional consequences.. **2021**, 262-263, 5-15	1
576	Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.. **2020**, 9, 6683-6690	0
575	A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy. **2021**, 33, 592-605	0
574	Concordance of Cytological Specimens with Histological Tissue for Detection of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Systematic Review. **2021**, 1-11	
573	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment.. **2021**, 9, 785410	0
572	Clinical research in oncology: in memory of Professor Gordon McVie.. **2022**, 16, 1340	

571	Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on F-FDG PET/CT for Patients with Colorectal Cancer.. **2022**, 2022, 2586245	0
570	Genetic Landscape of Multistep Hepatocarcinogenesis.. **2022**, 14,	2
569	Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection.. **2022**, 14,	1
568	Microfluidic Approaches and Methods Enabling Extracellular Vesicle Isolation for Cancer Diagnostics.. **2022**, 13,	1
567	Genomic Meta-analysis of Clear-cell Renal Cell Carcinoma (ccRCC): Aggregating Tumors to Resolve the Complexity of ccRCC.. **2022**, 81, 362-362	
566	Cells to Surgery Quiz: January 2022.. **2022**, 142, e9-e14	
565	A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies.. **2022**, 19, 20210803	1
564	Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours.. **2022**,	2
563	Sulfobetaine polymers for effective permeability into multicellular tumor spheroids (MCTSs).. **2022**,	
562	Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients.. **2022**, 13, 744-751	0
561	Cancer stem cells. **2022**, 187-204	
560	Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma.. **2022**, 12, e670	1
559	Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups.. **2022**,	1
558	Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report.. **2022**,	0
557	Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning.. **2022**, 13, 237-256	2
556	Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.. **2022**,	3
555	Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition.. **2022**,	0
554	How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?. **2022**, 12,	2

553	Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma.	
552	Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.. **2021**, 8, 788869	1
551	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.. **2022**, 60, 100811	3
550	Potential Use of CTCs as Biomarkers in Renal Cancer Patients.. **2022**, 12,	0
549	Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.. **2022**, 14,	2
548	Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.. **2022**, 14,	1
547	A physical mechanism of heterogeneity and micro-metastasis in stem cells, cancer cells, and cancer stem cells.. **2022**, 156, 075103	
546	A Multicancer Malignant Pleural Effusion Diagnostic Test Using Hexokinase 2 and Single-Cell Sequencing.. **2022**,	3
545	Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells.. **2022**, 1	3
544	Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.. **2022**, 23,	3
543	Hyperpolarized C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study.. **2022**, 14,	0
542	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.. **2021**,	0
541	JAFFAL: detecting fusion genes with long-read transcriptome sequencing.. **2022**, 23, 10	2
540	Multi-Regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Cancer.	
539	Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL).. **2022**, 14,	2
538	The Role of Histogram-Based Textural Analysis of F-FDG PET/CT in Evaluating Tumor Heterogeneity and Predicting the Prognosis of Invasive Lung Adenocarcinoma.. **2022**, 31, 33-41	1
537	Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer.. **2022**, 12, 772770	0
536	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.. **2022**, 104, 102340	2

535	PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets.	
534	Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes.. **2022**, 1877, 188681	0
533	Large deviations of cancer recurrence timing. **2022**, 147, 1-50	
532	Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer.. **2022**, 21, 11769351221076062	3
531	Coping with paradoxical or flawed classifications and ontologies. **2022**, 155-201	
530	Liquid biopsy in kidney tumor. **2022**, 101-127	
529	Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFB and JNK Signaling.. **2022**, 2022, 5916692	0
528	Branching copy number evolution and parallel immune profiles across the regional tumor space of resected pancreatic cancer.. **2022**,	
527	The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?. **2022**, 13, 828875	5
526	Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer.. **2022**, 1	0
525	Lipid metabolism of cancer stem cells.. **2022**, 23, 119	2
524	Integration of multiple lineage measurements from the same cell reconstructs parallel tumor evolution. **2022**, 2, 100096	2
523	Analyzing Association between Expression Quantitative Trait and CNV for Breast Cancer Based on Gene Interaction Network Clustering and Group Sparse Learning. **2022**, 17,	
522	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.. **2022**,	0
521	A review on advances in F-FDG PET/CT radiomics standardisation and application in lung disease management.. **2022**, 13, 22	1
520	OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives.. **2022**, 13, 842203	0
519	Correlation between F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer.. **2022**, 47, 1255	0
518	Selective Single-Cell Expansion on a Microfluidic Chip for Studying Heterogeneity of Glioma Stem Cells.. **2022**,	0

517	Response of human glioblastoma cells to hyperthermia: Cellular apoptosis and molecular events.. **2022**, 75, 101751	0
516	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. **2021**, 5, 100	2
515	[Impression of the 1975 General Meeting of the Japan Nursing Association. Fulfilment and some disappointment]. **1975**, 31, 334-6	
514	All You Need is Color: Image Based Spatial Gene Expression Prediction Using Neural Stain Learning. **2021**, 437-450	0
513	The Complexity of Tumor Heterogeneity: Limitations and Challenges of the Pharmacogenomics in Cancer Treatment. **2022**, 23-45	
512	Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis.. **2022**,	0
511	Molecular Imaging and Radiomics. **2022**, 309-316	
510	Computational Approaches for the Investigation of Intra-tumor Heterogeneity and Clonal Evolution from Bulk Sequencing Data in Precision Oncology Applications.. **2022**, 1361, 101-118	
509	The impact of radiomics in diagnosis and staging of pancreatic cancer.. **2022**, 15, 26317745221081596	1
508	Mechanisms of lymphatic spread in colon cancer: insights from molecular and genetic studies. **2022**, 43-55	
507	The Dynamics of the Labelling Game: An Essay On FLT3 Mutated Acute Myeloid Leukaemia. **2022**, 121-132	
506	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing.. **2022**, 16, 11795549221075326	1
505	Molecular sensors for detection of tumor-stroma crosstalk.. **2022**, 154, 47-91	1
504	Tumor Heterogeneity and Molecular Characteristics of Glioblastoma Revealed by Single-Cell RNA-Seq Data Analysis.. **2022**, 13,	0
503	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. **2022**,	2
502	PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma.. **2022**, 14,	0
501	Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring.. **2022**,	
500	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.. **2022**,	4

499	Molecular Characterization of m6A Modifications in Non-Clear Cell Renal Cell Carcinoma and Potential Relationship with Pathological Types.. **2022**, 15, 1595-1608	
498	Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.. **2022**, 14,	9
497	Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer.	
496	Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.. **2022**, 5, 149-152	
495	Spatially Annotated Single Cell Sequencing for Unraveling Intratumor Heterogeneity.. **2022**, 10, 829509	0
494	Recent pharmacological approaches for the treatment of renal cell carcinoma.. **2022**, 1-9	
493	Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer.. **2022**, 12,	0
492	First passage time analysis of spatial mutation patterns reveals evolutionary dynamics of pre-existing resistance in colorectal cancer.	
491	Statistical Mechanical theory for spatio-temporal evolution of Intra-tumor heterogeneity in cancers: Analysis of Multiregion sequencing data.	
490	Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.. **2022**, 23, 254-267	1
489	Challenges in the Use of Targeted Therapies in NSCLC.. **2022**,	1
488	[6. Imaging Biopsy for Assisting Cancer Precision Therapy -Information Extracted from Radiomics].. **2022**, 78, 219-224	
487	What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination.. **2022**, 11, 2038403	0
486	Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.. **2022**, 8, eabm1831	2
485	Current Trends in Computational chemistry for Breast Cancer.. **2022**, 19,	
484	Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?. **2022**,	2
483	Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.. **2022**, 12, 856974	4
482	Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.. **2022**, 14,	2

481	Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review.. **2022**, 1	1
480	Bone and Soft Tissue Tumors: Horizons in Radiomics and Artificial Intelligence.. **2022**, 60, 339-358	
479	Resolving clonal substructure from single cell genomic data using CopyKit.	0
478	Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.. **2022**,	0
477	Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report.. **2022**, 10, 2836-2843	0
476	Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumors treated with entrectinib.. **2022**,	0
475	Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors. **2022**, 6, 11-22	
474	Genetic heterogeneity and therapeutic target detection through microdissection in solid-type adenoid cystic carcinoma.. **2022**,	1
473	Clinical Applications of Circulating Tumour Cells and Circulating Tumour´DNA in Non-Small Cell Lung´Cancer-An Update.. **2022**, 12, 859152	0
472	Simulating the Dynamic Intra-Tumor Heterogeneity and Therapeutic Responses.. **2022**, 14,	2
471	Gattaca: Base pair resolution mutation tracking for somatic evolution studies using agent-based models.. **2022**,	0
470	Containing Cancer with Personalized Minimum Effective Dose.	1
469	Clinical translation of patient-derived tumour organoids- bottlenecks and strategies.. **2022**, 10, 10	2
468	KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.. **2022**, 37, 895	0
467	Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.. **2022**,	0
466	Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity.. **2022**, 14,	1
465	Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. **2022**, 10, 2834-2841	
464	MaasPenn Radiomics Reproducibility Score: A Novel Quantitative Measure for Evaluating the Reproducibility of CT-Based Handcrafted Radiomic Features.. **2022**, 14,	0

463	Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care.. **2022**, 12,	1
462	Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy.. **2022**, 12, e645	0
461	ctDNA as a biomarker of progression in oesophageal adenocarcinoma. **2022**, 100452	1
460	Imaging of Oligometastatic Disease.. **2022**, 14,	0
459	Multi-Region Genomic Landscape Analysis for the Preoperative Prediction of Lymph Node Metastasis in Esophageal Carcinoma.. **2022**, 13, 830601	
458	MOCA for Integrated Analysis of Gene Expression and Genetic Variation in Single Cells.. **2022**, 13, 831040	
457	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. **2022**,	1
456	Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.. **2022**, 14, e23783	
455	Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer.. **2022**, 14,	1
454	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics.. **2022**, 12, 871252	0
453	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. **2022**, JCO2102767	7
452	Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.. **2022**, 14,	2
451	THP-1 reference data: proposal of an in vitro branched evolution model for cancer cell lines.. **2022**,	
450	Origins and timing of emerging lesions in advanced renal cell carcinoma.. **2022**,	
449	Cancer: More than a geneticist Pandora box. **2022**, 47,	
448	Glioma Grading Prediction Using Multiparametric Magnetic Resonance Imaging-based Radiomics Combined with Proton Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging.. **2022**,	0
447	Inoperable metastatic colorectal cancer with primary tumour : Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).. **2022**, 16, 40	
446	Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.. **2021**, 11, 762184	5

445	The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?. **2021**, 10,	1
444	A pipeline for copy number profiling of single circulating tumor cells to assess intra-patient tumor heterogeneity.. **2021**,	2
443	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma.. **2021**, 10, 4423-4444	0
442	Spatial structure governs the mode of tumour evolution.. **2021**,	6
441	Circulating Tumor DNA in Oncology. **2021**, 9, 2198	
440	Spatial models of tumour evolution.. **2021**,	0
439	Prediction of high-risk liver cancer patients from their mutation profile: Benchmarking of mutation calling techniques.	
438	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. **2021**,	1
437	Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses.. **2021**, e2103360	1
436	Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. **2021**,	1
435	WILD-seq: Clonal deconvolution of transcriptomic signatures of sensitivity and resistance to cancer therapeutics in vivo.	
434	Convolutional Neural Network Addresses the Confounding Impact of CT Reconstruction Kernels on Radiomics Studies.. **2021**, 7, 877-892	0
433	Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.. **2021**, 13,	2
432	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.. **2021**,	4
431	Traditional chinese medicine syndromes classification associates with tumor cell and microenvironment heterogeneity in colorectal cancer: a single cell RNA sequencing analysis. **2021**, 16, 133	1
430	A computational prognostic model of lncRNA signature for clear cell renal cell carcinoma with genome instability. **2021**, 1-10	1
429	Urologic Cancer Molecular Biology.	
428	Understanding Drug Sensitivity and Tackling Resistance in Cancer.. **2022**,	1

427	Single-Cell Sequencing and Its Applications in Liver Cancer.. **2022**, 12, 857037	1
426	Inter-assay variability of next-generation sequencing-based gene panels.. **2022**, 15, 86	
425	The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease.. **2022**, 14,	0
424	Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma.. **2022**, 14, e24175	
423	Evolving Insights Into the Biological Function and Clinical Significance of Long Noncoding RNA in Glioblastoma.. **2022**, 10, 846864	2
422	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. **2022**, 12, 780186	1
421	Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.. **2022**,	1
420	Image_1.jpeg. **2019**,	
419	Image_2.png. **2019**,	
418	DataSheet_1.docx. **2020**,	
417	Image_1.TIF. **2019**,	
416	Image_2.TIF. **2019**,	
415	Image_3.TIF. **2019**,	
414	Table_1.DOCX. **2019**,	
413	Image_1.jpg. **2020**,	
412	Image_2.jpg. **2020**,	
411	Table_1.docx. **2020**,	
410	Table_1.DOCX. **2020**,	

409 Table_1.XLSX. **2019**,

408 Image_1.JPEG. **2020**,

407 Image_2.JPEG. **2020**,

406 Table_1.XLSX. **2020**,

405 Data_Sheet_1.PDF. **2019**,

404 Data_Sheet_1.PDF. **2020**,

403 Data_Sheet_2.PDF. **2020**,

402 Table_1.DOCX. **2020**,

401 Table_2.DOCX. **2020**,

400 Data_Sheet_1.pdf. **2020**,

399 Data_Sheet_2.xlsx. **2020**,

398 Data_Sheet_1.docx. **2019**,

397 Data_Sheet_2.xlsx. **2019**,

396 Data_Sheet_1.PDF. **2019**,

395 Data_Sheet_1.DOC. **2020**,

394 Data_Sheet_1.xlsx. **2019**,

393 Data_Sheet_2.xlsx. **2019**,

392 Image_1.TIF. **2019**,

391 Image_2.TIF. **2019**,

390 Image_3.TIF. **2019**,

389 Image_4.TIF. **2019**,

388 Image_5.TIF. **2019**,

387 Table_1.DOCX. **2019**,

386 table_1.docx. **2018**,

385 Presentation_1.pptx. **2020**,

384 Presentation_2.pptx. **2020**,

383 Presentation_3.pptx. **2020**,

382 Presentation_4.pptx. **2020**,

381 Presentation_5.pptx. **2020**,

380 Table_1.docx. **2020**,

379 Table_2.xlsx. **2020**,

378 Table_3.xlsx. **2020**,

377 Table_4.docx. **2020**,

376 Table_1.DOCX. **2020**,

375 Data_Sheet_1.PDF. **2018**,

374 CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.. **2022**, 1 0

373	Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG.. **2022**, 346, 158-168	0
372	Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.. **2022**,	
371	Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study. **2021**,	0
370	Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma.. **2022**,	6
369	Optimal strategy and benefit of pulsed therapy depend on tumor heterogeneity and aggressiveness at time of treatment initiation.. **2022**,	0
368	New and effective method to develop primary hepatocytes from liver cancer patients.. **2022**, 15353702221085534	
367	Heterogeneity of the tumor immune microenvironment and its clinical relevance.. **2022**, 11, 24	1
366	OUP accepted manuscript.	0
365	Clinical validation of a next-generation sequencing-based multi-cancer early detection "liquid biopsy" blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study.. **2022**, 17, e0266623	2
364	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.. **2022**, 42, 1-19	0
363	Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.. **2022**, 14,	
362	Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report.. **2022**, 14, 1595-1602	0
361	Hepatocellular Carcinoma: The Role of MicroRNAs. **2022**, 12, 645	2
360	Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.. **2022**,	
359	LDH-A-Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses.. **2022**, 14,	0
358	Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.. **2022**,	1
357	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. **2022**, 12,	
356	Prognostic Value of SPOCD1 in Esophageal Squamous Cell Carcinoma: A Comprehensive Study Based on Bioinformatics and Validation. **2022**, 13,	0

355 The translational challenges of precision oncology.. **2022**, 3

354 Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?. **2022**, 1 0

353 Radiogenomics: A Valuable Tool for the Clinical Assessment and Research of Ovarian Cancer.. **2022**, 46, 371-378

352 High-throughput single-cell sequencing in cancer research.. **2022**, 7, 145 1

351 Prognostic significance of dynamin-related protein 1 expression in advanced lung adenocarcinoma.. **2022**, 234, 153931

350 Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis.. **2022**, 15, 59 3

349 The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma.. **2022**, 101819

348 Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.. **2022**, 17, e0267362 0

347 Extracellular Vesicle-Based Multianalyte Liquid Biopsy as a Diagnostic for Cancer.. **2022**, 1

346 Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma.. **2022**, 27, 39 0

345 The risk of increasing tumor malignancy after PET diagnosis. **2022**,

344 Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report.. **2022**, 20, 157

343 Cancer evolution: special focus on the immune aspect of cancer.. **2022**, 0

342 Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape.. **2022**, 0

341 A Deep Learning Model Based on MRI and Clinical Factors Facilitates Noninvasive Evaluation of KRAS Mutation in Rectal Cancer.. **2022**, 0

340 Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.. **2022**, 13, 2485 4

339 Artificial Intelligence in Kidney Cancer.. **2022**, 42, 1-11 0

338 Development of Novel Cancer Biomarkers for Diagnosis and Prognosis. **2022**, 277-343

337	Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches. **2022**, 14, 2484	
336	Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy.	
335	Expression of GOT2 Is Epigenetically Regulated by DNA Methylation and Correlates with Immune Infiltrates in Clear-Cell Renal Cell Carcinoma. **2022**, 44, 2472-2489	1
334	TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling.	
333	Acquired chemoresistance drives spatial heterogeneity, chemoprotection and collective migration in pancreatic tumor spheroids. **2022**, 17, e0267882	
332	The Machine Learning Model for Distinguishing Pathological Subtypes of Non-Small Cell Lung Cancer. **2022**, 12,	0
331	Prediction of risk-associated genes and high-risk liver cancer patients from their mutation profile: Benchmarking of mutation calling techniques.	0
330	Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation. **2022**, 13,	0
329	Advances in engineered exosomes towards cancer diagnosis and therapeutics.	0
328	Application of Artificial Intelligence for Designing Cancer Nanomedicine. **2022**, 4-15	
327	Multiplexed imaging in oncology. **2022**, 6, 527-540	3
326	Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report. **2022**, 58, 706	0
325	Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis Pipeline.	0
324	The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. **2022**, 9,	
323	SETD2: from chromatin modifier to multipronged regulator of the genome and beyond. **2022**, 79,	1
322	Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis. **2022**, 22,	
321	Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity. 2201539	0
320	Electron acceleration based on Bloch surface waves. **2022**, 29, 063105	

319 Predictive Biomarkers in Breast Cancer: ER, PR, and HER-2/NEU. **2022**, 293-312

318 Metabolic Reprogramming of Circulating Tumor Cells for Metastasis. **2022**, 175-183

317 Radiation Therapy for Extracranial Oligometastatic Disease. **2022**, 681-695

316 In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.

315 Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. 12, 1

314 Sparse-spectral microendoscopy for real-time visualization of tumor cell phenotype and microenvironment spatial heterogeneity in vivo. 0

313 A phylogenetic approach to study the evolution of somatic mutational processes in cancer. **2022**, 5, 0

312 Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer. 12, 0

311 Whole genome duplication in oral squamous cell carcinoma in patients younger than 50 years: implications for prognosis and adverse clinicopathological factors.

310 Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. **2022**, 14, 2867 2

309 Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. **2022**,

308 Characterization of gene cluster heterogeneity in single-cell transcriptomic data within and across cancer types. **2022**, 11, 0

307 Single-Cell Technologies: Advances in Single-Cell Migration and Multi-Omics. **2022**, 1, 246-261

306 Mapping Single Cell Transcriptomes in the Intra-Tumoural and Associated Territories of Kidney Cancer.

305 Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine. **2022**, 549-562

304 Intratumor Graph Neural Network of Tumor-Associated Collagen Signatures from Multiphoton Microscopy Empowers Prognosis of 995 Breast Cancer Patients. **2022**,

303 Use of Imaging Mass Cytometry in Studies of the Tissue Microenvironment. **2022**, 345-364 1

302 Microfluidics for the Isolation and Detection of Circulating Tumor Cells. **2022**, 389-412 0

301	MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling. **2022**, 21-27	
300	Identification of a differentiation-related prognostic nomogram based on single-cell RNA sequencing in clear cell renal cell carcinoma. **2022**, 12,	1
299	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma.	1
298	The era of 3D and spatial genomics. **2022**,	0
297	Evaluation of Radiomics Models Based on Computed Tomography for Distinguishing Between Benign and Malignant Thyroid Nodules. Publish Ahead of Print,	
296	Liquid biopsy in der gastrointestinalen Onkologie: Hype oder bald Realität?. **2022**, 20, 45-54	
295	Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study.	
294	Measuring competitive exclusion in non-small cell lung cancer. **2022**, 8,	3
293	Differences in actionable genomic alterations between brain metastases and non-brain metastases in patients with non-small cell lung cancer. **2022**, 61,	
292	The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma. **2022**,	0
291	Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research. **2022**, 13,	
290	Liquid profiling for cancer patient stratification in precision medicine—Current status and challenges for successful implementation in standard care. **2022**,	0
289	MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma. **2022**, 22,	0
288	Detection of genes with differential expression dispersion unravels the role of autophagy in cancer progression.	
287	A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma. 12,	1
286	Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients. **2022**,	0
285	Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.	1
284	Sandwich Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients. 12,	0

283	Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas. **2022**, 14, 3381	2
282	The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization. **2022**, 14, 3349	0
281	Genomic Sequencing Should Be Part of the Standard of Care for Most Urologic Cancers: For. **2022**,	0
280	Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. 13,	1
279	Development and Validation of Multiparametric MRI-Based Radiomics Models for Preoperative Risk Stratification of Endometrial Cancer.	1
278	Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine. 4,	1
277	Histologically resolved multiomics enables precise molecular profiling of human intratumor heterogeneity. **2022**, 20, e3001699	
276	Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. **2022**, 188, 114449	3
275	Understanding Intra-tumour Heterogeneity—The Next Holy Grail of Cancer Therapeutics?. **2014**, 43, 72-73	
274	Cancer Biology and Implications for the Perioperative Period. **2023**, 24-45	
273	Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. **2022**, 14, 3628	0
272	The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. **2022**, 101819	
271	Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma.	0
270	A Detailed Overview About the Single-Cell Analyses of Solid Tumors Focusing on Colorectal Cancer. 28,	0
269	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. **2022**, 10, e004848	1
268	Intratumor graph neural network recovers hidden prognostic value of multi-biomarker spatial heterogeneity. **2022**, 13,	0
267	Timing evolution of lobular breast cancer through phylogenetic analysis. **2022**, 82, 104169	
266	Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning. **2022**, 82, 2792-2806	1

265	Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters. **2022**, 9,	0
264	A systematic review of prognosis predictive role of radiomics in pancreatic cancer: heterogeneity markers or statistical tricks?.	2
263	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. **2022**, 12, 1799	2
262	Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. 13,	0
261	An Epigenetic Role of Mitochondria in Cancer. **2022**, 11, 2518	5
260	State-dependent evolutionary models reveal modes of solid tumor growth.	
259	Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. **2022**, 14, 3973	
258	Investigating Morphologic Correlates of Driver Gene Mutation Heterogeneity via Deep Learning. **2022**, 82, 2672-2673	
257	Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.	0
256	Stellenwert der Liquid Biopsy im Rahmen der Therapie des kolorektalen Karzinoms. **2022**, 9, 43-47	
255	3D Amide Proton Transfer-Weighted Imaging for Grading Glioma and Correlating IDH Mutation Status: Added Value to 3D Pseudocontinuous Arterial Spin Labelling Perfusion.	
254	Radiomics modelBased algorithm for preoperative prediction of pancreatic ductal adenocarcinoma grade.	0
253	Synthesis and Biological Evaluation of Steviol Derivatives with Improved Cytotoxic Activity and Selectivity. **2022**, 85, 1945-1958	0
252	Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. 1-45	2
251	Magnetic bead-based adsorption strategy for exosome isolation. 10,	2
250	The clonal expression genes associated with poor prognosis of liver cancer. 13,	
249	Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma. **2022**, 28, 4376-4389	0
248	Raman spectroscopy and supervised learning as a potential tool to identify high-dose-rate -brachytherapy induced biochemical profiles of prostate cancer.	

247	Clinical Validation of Companion Diagnostics for the Selection of Patients with Non‐Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. **2022**,	0
246	Is Radiomics Growing Towards Clinical Practice?. **2022**, 12, 1373	2
245	Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients. **2022**, 2, 100165	0
244	Radiomics Signature to Predict Prognosis in Early-Stage Lung Adenocarcinoma (≤ 3 cm) Patients with No Lymph Node Metastasis. **2022**, 12, 1907	
243	Predicting chemotherapy response in non-small-cell lung cancer via computed tomography radiomic features: Peritumoral, intratumoral, or combined?. 12,	1
242	Untangling the web of intratumour heterogeneity. **2022**, 24, 1192-1201	0
241	Genetically Engineered Mouse Models (GEMMs) in Cancer Immunotherapy R&D. **2022**, 63-74	
240	Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma. **2022**, 22,	1
239	Proof of Concept: detection of cell free RNA from EDTA plasma in patients with lung cancer and non-cancer patients.	0
238	Cancer: Slaying the 9-headed Hydra. **2022**,	2
237	Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation. **2022**, 133, 106028	3
236	Deep View of HCC Gene Expression Signatures and Their Comparison with Other Cancers. **2022**, 14, 4322	0
235	MRI techniques for immunotherapy monitoring. **2022**, 10, e004708	0
234	Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma. **2022**, 630, 71-76	0
233	CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy. **2022**, 26, 101536	0
232	Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial ‐ Prodige 31 REMINET: An FFCD study. **2022**, 175, 31-40	0
231	Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis. **2022**, 61, 152044	0
230	Complementarity, Complexity and the Fokker‐Planck Equation; from the Microscale Quantum Stochastic Events to Fractal Dynamics of Cancer. **2022**, 19-54	0

229	UPP1 Promotes Lung Adenocarcinoma Progression through Epigenetic Regulation of Glycolysis. **2022**, 13, 1488	0
228	A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance. **2022**, 93-104	0
227	Integrative Transcriptome and Proteome Analyses of Clear Cell Renal Cell Carcinoma Develop a Prognostic Classifier Associated with Thrombus.	0
226	Molekulares Tumorboard Nierenzellkarzinom. **2022**, 1-4	0
225	Introduction of medical genomics and clinical informatics integration for p-Health care. **2022**, 1-37	1
224	A p53 transcriptional signature in primary and metastatic cancers derived using machine learning. 13,	0
223	Chromatin Variants Reveal the Genetic Determinants of Oncogenesis in Breast Cancer. **2022**, 12, a041322	0
222	Clinical trial design in the era of precision medicine. **2022**, 14,	3
221	Advances in liquid biopsy in neuroblastoma. **2022**,	1
220	Liquid biopsy: current technology and clinical applications. **2022**, 15,	8
219	Differentiation between spinal multiple myeloma and metastases originated from lung using multi-view attention-guided network. 12,	0
218	Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma. **2022**, 11, 2924	0
217	Cell Competition Shapes Metastatic Latency and Relapse.	0
216	Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma.	0
215	The evolutionary dynamics of extrachromosomal DNA in human cancers. **2022**, 54, 1527-1533	1
214	Precision Oncology for Biliary Tract Tumors: It Written in Blood!. **2022**,	0
213	Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. **2022**, 29, 6628-6634	1
212	A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. **2022**, 14,	0

211	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. **2022**, 100179	4
210	The role of protein acetylation in carcinogenesis and targeted drug discovery. 13,	1
209	Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. **2022**, 21,	0
208	Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. **2022**, 8,	0
207	A signature based on chromatin regulation and tumor microenvironment infiltration in clear cell renal cell carcinoma. **2022**, 14, 995-1013	0
206	Clone Phylogenetics Reveals Metastatic Tumor Migrations, Maps, and Models. **2022**, 14, 4326	0
205	Nondestructive protein sampling with electroporation facilitates profiling of spatial differential protein expression in breast tumors in vivo. **2022**, 12,	0
204	Discovering significant evolutionary trajectories in cancer phylogenies. **2022**, 38, ii49-ii55	0
203	The convergence of tumor suppressors on interferon pathway in kidney cancer and its therapeutic implication.	0
202	The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. **2022**, 14, 4693	2
201	Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker‐driven learning framework. **2022**, 8,	0
200	Functional Investigation of the Tumoural Heterogeneity of Intrahepatic Cholangiocarcinoma by In Vivo PET-CT Navigation: A Proof-of-Concept Study. **2022**, 11, 5451	0
199	Predictive validity in drug discovery: what it is, why it matters and how to improve it.	4
198	The histone methyltransferase SETD2 negatively regulates cell size. **2022**, 135,	0
197	Marker-free co-selection for successive rounds of prime editing in human cells. **2022**, 13,	0
196	Deciphering Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma Utilizing Clinicopathologic and Molecular Platforms. **2022**,	0
195	Quantitative Framework for Bench-to-Bedside Cancer Research. **2022**, 14, 5254	0
194	Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma. 12,	0

193	Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. **2022**, 6,	1
192	Cancer Genomics and Evolution. 1-30	0
191	Evaluating the Diagnostic Potentials of Circulating Tumor DNA against Melanoma: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-10	0
190	Application of support vector machine algorithm for early differential diagnosis of prostate cancer. **2022**,	0
189	Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer.	0
188	Refphase: Multi-sample reference phasing reveals haplotype-specific copy number heterogeneity.	0
187	Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management. **2022**, 14, 5370	0
186	Gene expression-based dissection of inter-histotypes, intra-histotype and intra-tumor heterogeneity in pediatric tumors. **2022**, 12,	0
185	Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.	0
184	Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. **2022**, 29, 7832-7841	0
183	Editorial: Current innovations in GI-oncology: Where do we stand?. 12,	0
182	Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-B via ANXA1-dependent ubiquitination of NEMO.	0
181	Ecology and games in cancer: new insights into the disease. **2022**, 114, 347-351	0
180	The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?. **2022**, 14, 5352	0
179	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. 12,	1
178	Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies. **2022**, 12,	1
177	Geostatistical Modeling and Heterogeneity Analysis of Tumor Molecular Landscape. **2022**, 14, 5235	0
176	Cellular barcoding to decipher clonal dynamics in disease. **2022**, 378,	0

175	Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma.	0
174	Geographically Weighted Linear Combination Test for Gene Set Analysis of a Continuous Spatial Phenotype as applied to Intratumor Heterogeneity.	0
173	Global research trends on precision oncology: A systematic review, bibliometrics, and visualized study. **2022**, 101, e31380	0
172	Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders. **2022**, 14, 5378	0
171	Evo-devo perspectives on cancer.	1
170	Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and ′future ′therapeutic landscape for clinicians.	1
169	A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. **2022**, 23, 13322	0
168	CD79A Work as a Potential Target For The Prognosis of Patients With HNSCC: Analysis of Immune Cell Infiltration In Head and Neck Squamous Cell Carcinoma Based on The CIBERSORTx Deconvolution Algorithm.	0
167	Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.	0
166	Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis. 34,	0
165	Molecular monitoring in endometrial cancer □ready for prime time?.	0
164	Development of a novel NGS methodology for ultrasensitive circulating tumour DNA detection as a tool for early-stage breast cancer diagnosis.	0
163	Role of extracellular vesicles in cancer-specific interactions between tumour cells and the vasculature. **2022**,	1
162	The need for evolutionary theory in cancer research.	0
161	Towards an accurate and robust analysis pipeline for somatic mutation calling. 13,	0
160	Spatially resolved transcriptomics: advances and applications. Publish Ahead of Print,	0
159	Multidimensional Quantitative Measurement of Cancer Chemoresistance through Differential ZIF-8 Nanoparticle Cellular Retention.	0
158	Genomic profiling identifies putative pathogenic alterations in non-small cell lung cancer brain metastases. **2022**, 100435	0

157	Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). **2022**, 20,	0
156	Prognostic value of textural features obtained from F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy.	0
155	Targeting intra-tumoral heterogeneity of human brain tumors with in vivo imaging: A roadmap for imaging genomics from multiparametric MR signals.	0
154	Very large hidden genetic diversity in one single tumor Evidence for tumors-in-tumor.	0
153	Challenges in neoantigen-directed therapeutics. **2022**,	1
152	Radiomics based on readout-segmented echo-planar imaging (RS-EPI) diffusion-weighted imaging (DWI) for prognostic risk stratification of patients with rectal cancer: a two-centre, machine learning study using the framework of predictive, preventive, and personalized medicine.	0
151	Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer. **2022**, 108445	0
150	Nanostructures and Nanotechnologies for the Detection of Extracellular Vesicle. 2200201	0
149	Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. **2022**, 10, 2953	1
148	Genetic heterogeneity of liver cancer stem cells. **2022**,	0
147	Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. **2022**, 23, 14224	0
146	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. **2022**, 895-915	0
145	Chapter 7. Cell Patterning to Mimic Tumor Anatomy. **2022**, 163-196	0
144	Multiplexed analysis of signalling proteins at the single-immune cell level.	0
143	Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. **2023**, 47, 12-19	0
142	Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. **2023**, 36, 100864	0
141	Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays. **2023**, 67, 101888	0
140	MRI Radiomics Signature of Pediatric Medulloblastoma Improves Risk Stratification Beyond Clinical and Conventional MR Imaging Features.	0

139	Preoperative Computed Tomography Radiomics Analysis for Predicting Receptors Status and Ki-67 Levels in Breast Cancer. **2022**, 45, 526-533	0
138	Cell-cell interactions that drive tumorigenesis in Drosophila. **2022**, 16, 367-381	1
137	The coming decade in precision oncology: six riddles. **2023**, 23, 43-54	1
136	Breast Cancer Dataset, Classification and Detection Using Deep Learning. **2022**, 10, 2395	1
135	Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer. 13,	0
134	An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study. **2022**, 24,	0
133	Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy. **2022**, 5, e2243119	0
132	Clinicopathologic and genomic characterizations of brain metastases using a comprehensive genomic panel. 9,	0
131	Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma. **2022**, 22,	0
130	Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma. **2022**, 20, 223-234	0
129	Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles. **2022**, 19, 1256-1275	2
128	Analyzing rare mutations in metagenomes assembled using long and accurate reads.	0
127	Organoids. **2022**, 2,	6
126	Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data.	0
125	The Role of Cell-Free DNA in Cancer Treatment Decision Making. **2022**, 14, 6115	0
124	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. **2022**, 13,	0
123	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis. **2023**, 24, 146	0
122	Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. **2022**, 40, 1583-1599.e10	1

121	c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche. **2022**, 8, e11998	0
120	Spatial biology of cancer evolution.	4
119	Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.	0
118	Biology, vulnerabilities and clinical applications of circulating tumour cells.	1
117	Cancer organoid applications to investigate chemotherapy resistance. 9,	0
116	Rational combinations of targeted cancer therapies: background, advances and challenges.	1
115	Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. 11,	0
114	Circadian clock circuitry deconvolutes colorectal cancer and lung adenocarcinoma heterogeneity in a dynamic time-related framework.	0
113	Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies.	0
112	Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. **2022**,	1
111	Structural Determination of the Nanocomplex of Borate with Styrene–Maleic Acid Copolymer-Conjugated Glucosamine Used as a Multifunctional Anticancer Drug. **2022**, 5, 5953-5964	0
110	Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. **2022**, 14,	0
109	Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.	0
108	Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma. 12,	0
107	T-cell repertoire diversity: friend or foe for protective antitumor response?. **2022**, 41,	0
106	BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.	0
105	ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. **2022**, 7,	1
104	Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma.	0

103	Clinical application and detection techniques of liquid biopsy in gastric cancer. **2023**, 22,	1
102	Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer. **2023**, 40,	0
101	Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers. **2023**, 20, 1645	0
100	Evolution tumour models paving the way for understanding oral carcinogenesis.	0
99	Breast cancer heterogeneity and its implication in personalized precision therapy. **2023**, 12,	0
98	Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma.	0
97	ConDoR: Tumor phylogeny inference with a copy-number constrained mutation loss model.	0
96	Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study. **2023**, 21,	0
95	Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma. **2023**, 12, 349	0
94	New Tools for Lineage Tracing in Cancer In Vivo. **2023**, 7,	0
93	Grave-to-cradle: human embryonic lineage tracing from the postmortem body.	0
92	Functional-structural Sub-region Graph Convolutional Network (FSGCN): Application to the Prognosis of Head and Neck Cancer with PET/CT imaging. **2023**, 107341	0
91	Somatic variant detection from multi-sampled genomic sequencing data of tumor specimens using the ith.Variant pipeline. **2023**, 4, 101927	0
90	The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review.	0
89	Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer. **2023**, 12, 114	0
88	Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants. 12,	0
87	Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.	0
86	The need for integrated research autopsies in the era of precision oral medicine. **2023**,	0

85	Mechanisms of drug resistance in HCC. Publish Ahead of Print,	0
84	Exemplar Guided Deep Neural Network for Spatial Transcriptomics Analysis of Gene Expression Prediction. **2023**,	0
83	Tumour Genetic Heterogeneity in Relation to Oral Squamous Cell Carcinoma and Anti-Cancer Treatment. **2023**, 20, 2392	0
82	ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. **2023**, 1-34	0
81	The oligometastatic paradigm and the role of radiotherapy. **2023**, 23, 61-64	0
80	Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. **2023**, 24, 2288	0
79	Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.	0
78	Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues. 11, e14653	0
77	SERS Detection of Breast Cancer-Derived Exosomes Using a Nanostructured Pt-Black Template. 2200039	0
76	Application of radiomics in lung immuno-oncology.	0
75	Development of Multiplex Drop-Off Digital PCR Assays for Hotspot Mutation Detection of KRAS, NRAS, BRAF, and PIK3CA in the Plasma of Colorectal Cancer Patients. **2023**,	0
74	The Role of Exosomes in Epithelial-to-Mesenchymal Transition and Cell Functional Properties in Head and Neck Cancer. **2023**, 15, 2156	0
73	Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. **2023**, 83, 441-451	0
72	Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects. **2023**, 88, 100964	0
71	Metastasis in renal cell carcinoma: Biology and treatment. **2023**, 7, 100094	0
70	Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. **2023**, 34, 389-396	1
69	Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers. **2023**, 56, 24-31	0
68	TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling. **2023**, 42,	0

67	The epigenome and the many facets of cancer drug tolerance. **2023**, 1-39	0
66	Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy. 13,	0
65	Expression of Epithelial and Mesenchymal Markers in Plasmatic Extracellular Vesicles as a Diagnostic Tool for Neoplastic Processes. **2023**, 24, 3578	0
64	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. 13,	0
63	PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. **2023**, 558, 216095	0
62	Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma. **2023**, 2023, 1-31	0
61	Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma. **2023**, 12, 1526	0
60	Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach. **2023**, 24, 4014	0
59	Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma. **2023**, 13,	1
58	Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. **2023**, 11,	0
57	Reconstructing clonal tree for phylo-phenotypic characterization of cancer using single-cell transcriptomics. **2023**, 14,	0
56	Radiomic Features Associated with Lymphoma Development in the Parotid Glands of Patients with Primary Sjögren's Syndrome. **2023**, 15, 1380	0
55	Possible involvement of silent mutations in cancer pathogenesis and evolution.	0
54	CRISPR-Cas9 Targeted Enrichment and Next-Generation Sequencing for Mutation Detection. **2023**,	0
53	Utility of pre-treatment 18F-fluorodeoxyglucose PET radiomic analysis in assessing nodal involvement in cervical cancer. **2023**, 44, 375-380	0
52	Mapping Tumor Heterogeneity via Local Entropy Assessment: Making Biomarkers Visible.	0
51	Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. **2023**, 15, 1473	0
50	Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. **2023**, 24, 4615	1

49	Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution. **2023**, 14, 571	0
48	Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?. **2023**, 24, 4883	0
47	AI in Precision Medicine. **2023**, 200-209	0
46	Current Trends in Neoantigen-Based Cancer Vaccines. **2023**, 16, 392	0
45	Single-Cell and Transcriptome-Based Immune Cell-Related Prognostic Model in Clear Cell Renal Cell Carcinoma. **2023**, 2023, 1-15	0
44	Geographically weighted linear combination test for gene-set analysis of a continuous spatial phenotype as applied to intratumor heterogeneity. 11,	0
43	Detection of genes with differential expression dispersion unravels the role of autophagy in cancer progression. **2023**, 19, e1010342	0
42	State-dependent evolutionary models reveal modes of solid tumour growth. **2023**, 7, 581-596	0
41	First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer. **2023**, 19, e1010952	0
40	Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors.	0
39	Histological transformation to signet-ring cell carcinoma in a patient with clinically aggressive poorly differentiated adenocarcinoma of the ascending colon after response to chemotherapy plus cetuximab: a case report.	0
38	Reconstructing Clonal Evolution: A Systematic Evaluation of Current Bioinformatics Approaches. **2023**, 20, 5128	0
37	Automated cell isolation from photodegradable hydrogel based on fluorescence image analysis.	0
36	Association between Preoperative 18-FDG PET-CT SUVmax and Next-Generation Sequencing Results in Postoperative Ovarian Malignant Tissue in Patients with Advanced Ovarian Cancer. **2023**, 12, 2287	0
35	An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. **2023**, 24, 5648	0
34	Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials. **2023**, 15, 1808	0
33	Diagnostic classification of childhood cancer using multiscale transcriptomics. **2023**, 29, 656-666	0
32	Prognostic subtypes of thyroid cancer was constructed based on single cell and bulk-RNA sequencing data and verified its authenticity. **2023**, 23,	0

31	Intratumoral heterogeneity, treatment response, and survival outcome of ER -positive HER2 -positive breast cancer.	0
30	P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.	0
29	Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma. 13,	0
28	Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease From Early Cancer Detection to Individualized Cancer Treatment. **2023**, 15, 1924	0
27	Integrative analysis of transcriptomic landscape and urinary signature reveals prognostic biomarkers for clear cell renal cell carcinoma. 13,	0
26	How to Standardize Molecular Profiling Programs for Routine Patient Care. **2023**, 37-49	0
25	Towards targeted colorectal cancer biopsy based on tissue morphology assessment by compression optical coherence elastography. 13,	0
24	Whole-volume apparent diffusion coefficient histogram analysis for prediction of regional lymph node metastasis in periampullary carcinomas.	0
23	Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches. **2023**, 63-81	0
22	Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. **2023**, 14,	0
21	Precision Oncology: Evolving Clinical Trials across Tumor Types. **2023**, 15, 1967	0
20	Role of renal mass biopsy for diagnosis and management: Review of current trends and future directions.	0
19	Diagnostic and predictive value of liquid biopsy-derived exosome miR-21 for breast cancer: a systematic review and meta-analysis. 1-10	0
18	Spatial Transcriptomics Analysis of Gene Expression Prediction using Exemplar Guided Graph Neural Network.	0
17	Analytical device miniaturization for the detection of circulating biomarkers.	0
16	The evolution of lung cancer and impact of subclonal selection in TRACERx. **2023**, 616, 525-533	0
15	Insights into the metastatic cascade through research autopsies. **2023**,	0
14	Molecular portraits of lung cancer evolution. **2023**, 616, 435-436	0

13	The clonal heterogeneity of colon cancer with liver metastases.	0
12	Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771	0
11	Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. **2023**, 8,	0
10	Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer: An Extensive Multiregional Immunohistochemical Analysis. **2023**,	0
9	Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. **2023**, 13, 689	0
8	Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions.	0
7	Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors. 11,	0
6	A statistical learning method for simultaneous copy number estimation and subclone clustering with single cell sequencing data.	0
5	Precision medicine: Overview and challenges to clinical implementation. **2023**, 513-529	0
4	Mutation detection of urinary cell-free DNA via catch-and-release isolation on nanowires for liquid biopsy. **2023**, 115318	0
3	¿Se puede rescatar con irradiación la paciente con cáncer de mama oligometastasica?. **2023**, 100501	0
2	General aspects of cancer therapy. **2023**, 1-35	0
1	Bootstrap confidence for molecular evolutionary estimates from tumor bulk sequencing data. 3,	0